<SEC-DOCUMENT>0001213900-24-088119.txt : 20241016
<SEC-HEADER>0001213900-24-088119.hdr.sgml : 20241016
<ACCEPTANCE-DATETIME>20241016141003
ACCESSION NUMBER:		0001213900-24-088119
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20241016
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241016
DATE AS OF CHANGE:		20241016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38105
		FILM NUMBER:		241374223

	BUSINESS ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0217785-8k_180life.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ATNF="http://180lifesciences.com/20241016">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_ATNF_180lifesciences.com_20241016 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20241016_20241016 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001690080 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000004" name="dei:EntityCentralIndexKey">0001690080</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="atnf-20241016.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-10-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-16</xbrli:startDate>
        <xbrli:endDate>2024-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-162024-10-16_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-16</xbrli:startDate>
        <xbrli:endDate>2024-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-162024-10-16_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-16</xbrli:startDate>
        <xbrli:endDate>2024-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>FORM&#160;<span id="xdx_900_edei--DocumentType_c20241016__20241016_zgTOBXuaEPEj"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>PURSUANT TO SECTION
13 OR 15(d)&#160;OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES EXCHANGE
ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Date of Report (Date
of earliest event reported):&#160;<span id="xdx_904_edei--DocumentPeriodEndDate_c20241016__20241016_zJS3oESfJg3f"><ix:nonNumeric contextRef="AsOf2024-10-16" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">October 16, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityRegistrantName_c20241016__20241016_z0ev64QbNN58"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000011" name="dei:EntityRegistrantName">180 LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20241016__20241016_zI61UzO9Hpjk"><ix:nonNumeric contextRef="AsOf2024-10-16" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityFileNumber_c20241016__20241016_zxa6K0JXPUkf"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000013" name="dei:EntityFileNumber">001-38105</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20241016__20241016_zLKwRg9MN2N1"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000014" name="dei:EntityTaxIdentificationNumber">90-1890354</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction<br/>
    of Incorporation)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20241016__20241016_zWfD0OzWdxSh"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000015" name="dei:EntityAddressAddressLine1">3000 El Camino Real</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20241016__20241016_zUa0yxvgpWFd"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000016" name="dei:EntityAddressAddressLine2">Bldg. 4</ix:nonNumeric></span></b><b>, <span id="xdx_905_edei--EntityAddressAddressLine3_c20241016__20241016_zwTXzMOAldj1"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000017" name="dei:EntityAddressAddressLine3">Suite 200</ix:nonNumeric></span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20241016__20241016_z2jO0yTwmGhb"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000018" name="dei:EntityAddressCityOrTown">Palo
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Alto</ix:nonNumeric></span>,<span id="xdx_90E_edei--EntityAddressStateOrProvince_c20241016__20241016_zcNV66E6gKIa"> <ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000019" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressPostalZipCode_c20241016__20241016_zczMO3m4MFWd"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000020" name="dei:EntityAddressPostalZipCode">94306</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Registrant&#8217;s telephone
number, including area code:&#160;<b><span style="text-decoration: underline">(<span id="xdx_908_edei--CityAreaCode_c20241016__20241016_zjYJcVvL68e1"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000021" name="dei:CityAreaCode">650</ix:nonNumeric></span>)&#160;<span id="xdx_903_edei--LocalPhoneNumber_c20241016__20241016_zRveXqbalz4d"><ix:nonNumeric contextRef="AsOf2024-10-16" id="Fact000022" name="dei:LocalPhoneNumber">507-0669</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Check the appropriate&#160;box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see&#160;</i>General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.15pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--WrittenCommunications_c20241016__20241016_z62pB17jVdT8"><ix:nonNumeric contextRef="AsOf2024-10-16" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities
    Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--SolicitingMaterial_c20241016__20241016_zgaBrSOG1my4"><ix:nonNumeric contextRef="AsOf2024-10-16" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange
    Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementTenderOffer_c20241016__20241016_zlYj0WwDFM0k"><ix:nonNumeric contextRef="AsOf2024-10-16" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)&#160;under
    the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20241016__20241016_zprXiyAbaFA2"><ix:nonNumeric contextRef="AsOf2024-10-16" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)&#160;under
    the Exchange Act (17 CFR 240.13e 4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Securities registered
pursuant to Section 12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20241016__20241016__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zPvsotydVcl4"><ix:nonNumeric contextRef="From2024-10-162024-10-16_custom_CommonStockParValue0.0001PerShareMember" id="Fact000027" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--TradingSymbol_c20241016__20241016__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zATAEJJ7p1x7"><ix:nonNumeric contextRef="From2024-10-162024-10-16_custom_CommonStockParValue0.0001PerShareMember" id="Fact000028" name="dei:TradingSymbol">ATNF</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The&#160;<span id="xdx_904_edei--SecurityExchangeName_c20241016__20241016__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_z1Sz5gcjTLa3"><ix:nonNumeric contextRef="From2024-10-162024-10-16_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Stock Market LLC</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20241016__20241016__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zoRVfeISrGAf"><ix:nonNumeric contextRef="From2024-10-162024-10-16_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000030" name="dei:Security12bTitle">Warrants to purchase shares of Common Stock</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20241016__20241016__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zJVtEtzv1SEg"><ix:nonNumeric contextRef="From2024-10-162024-10-16_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000031" name="dei:TradingSymbol">ATNFW</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The&#160;<span id="xdx_90F_edei--SecurityExchangeName_c20241016__20241016__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zmJ7inx2Ub7j"><ix:nonNumeric contextRef="From2024-10-162024-10-16_custom_WarrantsToPurchaseSharesOfCommonStockMember" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)&#160;or
Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20241016__20241016_z87GQmSpQkIh"><ix:nonNumeric contextRef="AsOf2024-10-16" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a)&#160;of the Exchange Act.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
October 16, 2024, 180 Life Sciences Corp. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) entered into a warrant inducement agreement (the &#8220;<span style="text-decoration: underline">Inducement
Agreement</span>&#8221;) with a holder (the &#8220;<span style="text-decoration: underline">Holder</span>&#8221;) of certain of the Company&#8217;s existing warrants to purchase
shares of common stock (&#8220;<span style="text-decoration: underline">Existing Warrants</span>&#8221;), par value $0.0001 per share (the &#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;),
of the Company. Pursuant to the Inducement Agreement, the Holder agreed to exercise for cash Existing Warrants to purchase up to 954,118
shares of Common Stock at an exercise price of $3.48 per share during the period from the date of the Inducement Agreement until 1:15 p.m.,
Eastern Time, on October 16, 2024. The aggregate gross proceeds to be received by the Company will depend on the number of Existing Warrants
actually exercised by the Holder. If all of the Existing Warrants are exercised in connection with the Inducement Agreement, the Company
would anticipate receiving aggregate gross proceeds of up to approximately $3,320,331 from the exercise of the Existing Warrants before
deducting financial advisory fees and other expenses payable by us. There is, however, no guarantee that all of the Existing Warrants
will be exercised by the Holder in accordance with the Inducement Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
consideration of the Holder&#8217;s agreement to exercise the Existing Warrants in accordance with the Inducement Agreement, the Company
agreed to issue new unregistered Warrants to Purchase Shares of Common Stock (the &#8220;<span style="text-decoration: underline">New Warrants</span>&#8221;) to purchase a number
of shares of Common Stock equal to 200% of the number of shares of Common Stock issued upon exercise of the Existing Warrants (the &#8220;<span style="text-decoration: underline">New
Warrant Shares</span>&#8221;). The New Warrants will be immediately exercisable and have a term of exercise of five years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company agreed in the Inducement Agreement to file a registration statement on Form S-1 to register the resale of the New Warrant Shares
upon exercise of the New Warrants (the &#8220;<span style="text-decoration: underline">Resale Registration Statement</span>&#8221;) by November 15, 2024, and to use commercially
reasonable efforts to have such Resale Registration Statement declared effective by the Securities and Exchange Commission (&#8220;<span style="text-decoration: underline">Commission</span>&#8221;)
within sixty (60) calendar days following the date of filing with the Commission (or ninety (90) calendar days following the date of filing
with the Commission in the event of a &#8216;full review&#8217; by the Commission) and to keep the Resale Registration Statement effective
at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares. In the event that the Company fails to timely
deliver to the Holder the New Warrant Shares without restrictive legends, the Company has agreed to pay certain liquidated damages to
the Holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company expects to use the net proceeds from these transactions <span style="font-family: Times New Roman, Times, Serif">to advance the
commercialization of the technology gaming platform recently acquired by the Company, </span>and for working capital, and other general
corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
New Warrants will have an exercise price of $1.50 per share. The exercise price and the number of shares of Common Stock issuable upon
exercise of each New Warrant are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits,
stock combinations, reclassifications or similar events affecting the Common Stock. In addition, in certain circumstances, upon a fundamental
transaction, a holder of New Warrants will be entitled to receive, upon exercise of the New Warrants, the kind and amount of securities,
cash or other property that such holder would have received had they exercised the New Warrants immediately prior to the fundamental transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company may not affect the exercise of New Warrants, and the applicable Holder will not be entitled to exercise any portion of any such
New Warrant, which, upon giving effect to such exercise, would cause the aggregate number of shares of Common Stock beneficially owned
by the holder of such New Warrant (together with its affiliates) to exceed 4.99% or 9.99%, as applicable, of the number of shares of Common
Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms
of such New Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company engaged A.G.P./Alliance Global Partners (&#8220;<span style="text-decoration: underline">A.G.P.</span>&#8221;) to provide exclusive financial services in connection with
the transactions summarized above and, pursuant to a Financial Advisory Agreement between the Company and A.G.P., has agreed to pay A.G.P.
a financial advisory fee of $232,000. In addition, we have also agreed to reimburse A.G.P. for its accountable legal expenses in connection
with the exercise of the Existing Warrants and the issuance of the New Warrants of up to $65,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
foregoing descriptions of the Inducement Agreement, Financial Advisory Agreement and the New Warrants do not purport to be complete and
are qualified in their entirety by reference to the full text of the form of Inducement Agreement and form of Warrant to Purchase Shares
of Common Stock, which are filed as <span style="text-decoration: underline">Exhibits 10.1</span>, <span style="text-decoration: underline">10.2</span> and <span style="text-decoration: underline">4.1</span>, respectively, to this Current Report on Form 8-K
and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The securities described herein
have not been registered under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;), and may not be sold in
the United States absent registration or an applicable exemption from the registration requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The resale of the shares of
Common Stock issuable upon exercise of the Existing Warrants has been registered under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The disclosure required by
this Item and included in <span style="text-decoration: underline">Item 1.01</span> of this Current Report is incorporated herein by reference. Neither the New Warrants nor the
New Warrant Shares have been registered under the Securities Act, and may not be sold in the United States absent registration or an applicable
exemption from the registration requirements of the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If exercised in full, a total
of 954,118 shares of Common Stock will be issuable upon exercise of the Existing Warrants and 1,908,236 shares of Common Stock will be
issuable upon exercise of the New Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt">Exhibit No.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-size: 10pt">Description</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea021778501ex4-1_180life.htm"><span style="font-size: 10pt">Form of Warrant to Purchase Shares of Common Stock.</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="ea021778501ex10-1_180life.htm"><span style="font-size: 10pt">Form of Warrant Inducement Agreement, by and between the Company and
    Holder.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ea021778501ex10-2_180life.htm">Financial Advisory Agreement, dated as of October 16, 2024, between A.G.P./Alliance Global Partners and the Company.</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Date: October 16, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ Blair Jordan</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">Name:</span></td>
    <td style="width: 31%"><span style="font-size: 10pt">Blair Jordan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Interim Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kcFuwjAMhp+Ad7CqHREkFduht61iaBpsFSC2q1fcUdHGlZMyeKS95dIUNA5bFCmy7O//fytRNIxm/FhWJPD+sJzDmuqmQkewpIKETE5+In16TsC/S/osrRM0LpQXMGXPkGduR/EEfSOMHkpL2wS0Guu7cTwBrROt4X4RDbp+yqYot2RciRWg2UIm3EhJDuXUK6zxyIbrU7DakNiSjZcbqb79DbHSMbzwAb9Y9hbm8zQaDMMZRDPhtvFT06Mj05Ewraj2dranf29Ik7fWcZ28oXTL2TVnreQ7tLTaoZB9LfyKNZuV43y/oPqDxENaxbFW9+c8FxYcQ3OmwQYcuIBeAILCH85X+hnKBquW1EgppTOSkOEf12vZITQocOhYuOlpaPz3hBAXzx9IE5Xt -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea021778501ex4-1_180life.htm
<DESCRIPTION>FORM OF WARRANT TO PURCHASE SHARES OF COMMON STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN SECURED BY
SUCH SECURITIES.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT TO PURCHASE SHARES OF COMMON STOCK</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 LIFE SCIENCES CORP.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant Shares: [__]&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Original Issuance Date: October 17, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS WARRANT TO PURCHASE SHARES
OF COMMON STOCK (this &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [__], or its assigns (the &ldquo;<U>Holder</U>&rdquo;),
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on October 17, 2029
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from 180 Life Sciences, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), up to [__] shares of Common Stock, par value $0.0001 per share (the &ldquo;<U>Common Stock</U>&rdquo;),
of the Company (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one Warrant Share
under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;1. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated August 9, 2023 among the Company and the purchasers signatory
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as <B>Exhibit A </B>(the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of
any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date
on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Business Day of receipt of such notice. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered
on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution
of the Purchase Agreement, the Company agrees to deliver, or cause to be delivered, the Warrant Shares subject to such notice(s) by 4:00
p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date (as defined
below) for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is
received by such Warrant Share Delivery Date. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,
by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant
Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;<U>Exercise
Price</U>. The exercise price under this Warrant shall be $1.50 per share of Common Stock, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Cashless
Exercise</U>. Notwithstanding anything to the contrary set forth herein, if at the time of exercise hereof there is no effective registration
statement registering the issuance of the Warrant Shares to the Holder, or the prospectus contained therein is not available for the issuance
of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (y) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice
of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within
two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant
to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a
Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">(B) = the Exercise
Price, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">(X) = the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued
in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant
Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the VWAP of the Common Stock for such date (or
the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB
or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the
fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30&nbsp;a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted to the Holder by
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then
a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares
to, or resale of the Warrant Shares by, the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical
delivery of the Warrant Shares, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number
of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise
by the date that is the earliest of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise, (ii) one (1)
Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard
Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of
(i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall pa<FONT STYLE="font-size: 10pt">y </FONT>to the Holder, at the Holder&rsquo;s election either (A)
in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of
the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third
Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until the earlier of such
Warrant Shares being delivered or Holder rescinds such exercise or (B) the amount pursuant to a Buy-In pursuant to Section 2(d)(iv) hereof.
The Company agrees to maintain a registrar (which may be the Transfer Agent) that is a participant in the FAST program so long as this
Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement
period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect
on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares
of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall
be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder
in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise
of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)&nbsp;<U>Charges,
Taxes and Expenses</U>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <B>Exhibit B</B>, duly executed
by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees
to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic
delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii)&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder&rsquo;s Affiliates, (ii) any other Persons
acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates, and (iii) any other Persons whose beneficial ownership
of shares of Common Stock would or could be aggregated with the Holder&rsquo;s for the purposes of Section 13(d) (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall
include the number of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but
shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant
that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding
shares of Common Stock that was provided by the Company. In addition, a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)
the Company&rsquo;s most recent periodic or annual report filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;),
as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer
Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall
within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case,
the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of
the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of
outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election
of the Holder prior to the issuance of this Warrant, 9.99%) of the number of shares of Common Stock outstanding immediately after giving
effect to the issuance of the Warrant Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase
or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in
no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Warrant
Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase
in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions
of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e)
to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable solely as a result of the
Holder&rsquo;s Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of Common Stock or any other equity or equity equivalent securities payable in shares of Common
Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii)
subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split)
outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares
of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise
of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or reclassification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;[RESERVED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable
to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares
of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without
limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale
of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right
to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company (and
all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of the Company&rsquo;s (including its Subsidiaries, taken as a whole) assets in one or
a series of related transactions, (ii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of Common Stock or more than
50% of the voting power of the common equity of the Company, or (iii) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to
which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property (each, a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the
&ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant).&nbsp; For purposes of any such exercise, the determination of the Exercise Price shall
be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect
of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&nbsp; If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this
Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without
unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for
this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent
to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder.&nbsp; Upon the occurrence of any such Fundamental Transaction, the Successor Entity
shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant
and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise
every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction
Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;<U>[</U>RESERVED<U>]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case
may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If, while the Warrant is outstanding, (A) the Company declares a dividend (or any other distribution
in whatever form) on the shares of Common Stock, (B) the Company declares a cash dividend on or a redemption of the shares of Common Stock,
(C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any
shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company is required in connection with
a Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile
number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares
of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close,
and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares
of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the
validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file
such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be
expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;<U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period
of time deemed appropriate by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof, this Warrant and all
rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of
this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant
substantially in the form attached hereto as <B>Exhibit B </B>duly executed by the Holder or its agent or attorney and funds
sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment,
the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the
denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this
Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on
which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in
accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&nbsp;</FONT><U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities
Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions
or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that
the Holder or transferee of this Warrant, evidence compliance with applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;<U>Currency</U>.
All dollar amounts referred to in this Warrant are in United States Dollars (&ldquo;<U>U.S. Dollars</U>&rdquo;). All amounts owing under
this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent
amount in accordance with the Exchange Rate on the date of calculation. &ldquo;<U>Exchange Rate</U>&rdquo; means, in relation to any amount
of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street
Journal (NY edition) on the relevant date of calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Section&nbsp;5. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;<U>Authorized
Shares</U>. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued
shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying the Warrant upon the
exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full
authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights
under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued
and delivered, as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market
upon which the Common Stock may be listed. The Company covenants that all Warrant Shares underlying this Warrant, which may be issued
and delivered upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Except and to the extent as waived or
consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation
or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights
of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not
increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately prior to such increase
in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully
paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain
all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable
the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Before taking any action which would
result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall
obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies
having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder
in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any shares of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">******************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Signature Page Follows</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">180 LIFE SCIENCES CORP.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TO: 180 LIFE SCIENCES CORP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) The undersigned hereby
elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) Payment shall take the
form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif">in
lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif">if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[SIGNATURE OF HOLDER]</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Investing Entity: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature of Authorized Signatory of Investing Entity</I>: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Authorized Signatory: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title of Authorized Signatory: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT B</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="width: 52%; border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Please Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Please Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Phone Number:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">14</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea021778501ex10-1_180life.htm
<DESCRIPTION>FORM OF WARRANT INDUCEMENT AGREEMENT, BY AND BETWEEN THE COMPANY AND HOLDER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>180 Life Sciences Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3000 El Camino Real, Building 4, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Palo Alto, CA 94306</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">October 16, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Holders of July 2022 Common Stock Purchase
Warrants, December 2022 Common Stock Purchase Warrants, April 2023 Common Stock Purchase Warrants, August 2023 Common Stock Purchase Warrants,
and December 2023 Common Stock Purchase Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 0.5in">Re:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><U>Inducement Offer to Exercise Existing Common Stock Purchase Warrants</U></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 LIFE SCIENCES CORP. (the
&ldquo;<U>Company</U>&rdquo;) is pleased to offer (this &ldquo;<U>Inducement Offer</U>&rdquo;) to you (&ldquo;<U>Holder</U>&rdquo;, &ldquo;<U>you</U>&rdquo;
or similar terminology) the opportunity to receive new warrants to purchase up to a number of shares (the &ldquo;<U>New Warrant Shares</U>&rdquo;)
of Common Stock, par value $0.0001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), equal to 200% of the number of Warrant Shares issued
pursuant to the exercise of Common Stock Purchase Warrants currently held by you and issued to you on July 20, 2022 (the &ldquo;<U>July
2022 Warrants</U>&rdquo;), December 22, 2022 (the &ldquo;<U>December 2022 Warrants</U>&rdquo;), April 10, 2023 (the &ldquo;<U>April 2023
Warrants</U>&rdquo;), August 14, 2023 (the &ldquo;<U>August 2023 Warrants</U>&rdquo;) and December 1, 2023 (the &ldquo;<U>December 2023
Warrants</U>&rdquo; and together, with the July 2022 Warrants, December 2022 Warrants, April 2023 Warrants and August 2023 Warrants, the
&ldquo;<U>Existing Warrants</U>&rdquo;), as more particularly set forth on the signature page hereto, in consideration for exercising
for cash any or all such Existing Warrants. The issuance, or resale, of shares of Common Stock underlying (i) the July 2022 Warrants,
December 2022 Warrants and April 2023 Warrants were registered pursuant to an effective registration statement on Form S-1 (File No. 333-271703)
(the &ldquo;<U>1st Resale Registration Statement</U>&rdquo;); (ii) the August 2023 Warrants were registered pursuant to an effective registration
statement on Form S-1 (File No. 333-272749) (the &ldquo;<U>Primary Offering Registration Statement</U>&rdquo;); and (iii) the December
2023 Warrants were registered pursuant to an effective registration statement on Form S-1 (File No. 333-276796) (the &ldquo;<U>2nd Resale
Registration Statement</U>&rdquo;). The 1st Resale Registration Statement and 2nd Resale Registration Statement were converted to a registration
statement on Form S-3 (File No. 333-276796) pursuant to Rule 429 under the Securities Act (as defined herein) pursuant to a Post-Effective
Amendment No. 1 to Form S-1 on Form S-3 filed on April 22, 2024 and declared effective on April 24, 2024. The shares of Common Stock underlying
the Existing Warrants are referred to herein as the &ldquo;<U>Warrant Shares</U>&rdquo; and the registration statements referenced in
the foregoing sentences are referred to herein as the &ldquo;<U>Registration Statements</U>.&rdquo; The Registration Statements are currently
effective and, upon exercise of the Existing Warrants pursuant to this letter agreement (the &ldquo;<U>Inducement Agreement</U>&rdquo;
and together with the Existing Warrants and the New Warrants, the &ldquo;<U>Transaction Documents</U>&rdquo;), will be effective for the
issuance or resale of the Warrant Shares, as applicable. Capitalized terms not otherwise defined herein shall have the meanings set forth
in the New Warrants (as defined hereinafter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is making you
this offer during the period from the date of this Inducement Offer set forth above and until [&#9679;]p.m., Eastern Time, on&nbsp;October
16, 2024&nbsp;(the &ldquo;<U>Exercise Period</U>&rdquo;). Exercise of the Existing Warrants may be made, in whole or in part, at any time
or times during the Exercise Period by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail
attachment) of the Notice of Exercise attached to the Existing Warrants, as applicable; provided, that the exercise of Existing Warrants
will be accompanied by payment in full of the Amended Exercise Price to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company desires to amend
the Exercise Price of the Existing Warrants to $3.48 per share (which includes the $0.125 charge for the New Warrants in compliance with
the Nasdaq rules) (the &ldquo;<U>Amended Exercise Price</U>&rdquo;). In consideration for exercising Existing Warrants held by Holder
and each time that the Holder exercises Existing Warrants pursuant to the terms of this Inducement Offer (the &ldquo;<U>Warrant Exercise</U>&rdquo;),
the Company hereby offers to issue you or your designees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) for exercising Existing
Warrants, new unregistered Common Stock purchase warrants ( &ldquo;<U>New Warrant</U>&rdquo;) pursuant to Section 4(a)(2) of the Securities
Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), to purchase up to a number of shares (the &ldquo;<U>New Warrant Shares</U>&rdquo;)
of Common Stock equal to 200% of the number of Warrant Shares issued pursuant to such exercise of Existing Warrants, which New Warrants
shall be substantially in the form as set forth in <B><U>Exhibit B</U></B> hereto, will be exercisable at any time on or after the Closing
Date, and have a term of exercise of five (5) years at an exercise price per share equal to $1.50 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The New Warrant certificates
will be delivered within one (1) Trading Day following the Warrant Exercise, and such New Warrants, together with any underlying shares
of Common Stock issued upon exercise of the New Warrants, shall, unless and until registered, contain customary restrictive legends and
other language typical for an unregistered warrant and unregistered shares. Notwithstanding anything herein to the contrary, in the event
that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (&ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo;) set forth in Section 2(e) of the Existing Warrants (or, if applicable and at the Holder&rsquo;s election, 9.99%),
the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the maximum number
of Warrant Shares permitted thereunder, as directed by the Holder, with the balance to be held in abeyance until notice from the Holder
that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced through the
Existing Warrants which shall be deemed prepaid thereafter (including the payment in full of the exercise price), and exercised pursuant
to a Notice of Exercise in the Existing Warrants (provided no additional exercise price shall be due and payable). The parties hereby
agree that the Beneficial Ownership Limitation for purposes of the Existing Warrants is as set forth on the Holder&rsquo;s signature page
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Expressly subject to the paragraph
immediately following this paragraph below, Holder may accept this offer by signing this letter below, which constitutes the Holder&rsquo;s
acceptance to exercise Existing Warrants at the Holder&rsquo;s own discretion subject to the Beneficial Ownership Limitation set forth
in Section 2(e) of the Existing Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agrees to the
representations, warranties and covenants set forth on <B><U>Annex A</U></B> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The Holder represents and warrants
that, as of the date hereof, the Holder is fully aware of, and has reviewed all of the Company&rsquo;s public filings and acknowledges that
the Company&rsquo;s Common Stock may be delisted from the Nasdaq Capital Market at a future date if the Company does not regain compliance with
the continued listing requirements under Nasdaq rules. For more information, please see the Company&rsquo;s Current Reports on Form 8-K filed
on May 15, 2024, May 21, 2024, July 2, 2024, July 23, 2024, October 3, 2024 and October 9, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holder represents and warrants
that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an &ldquo;accredited investor&rdquo;
as defined in Rule 501 of Regulation D promulgated under the Securities Act, and agrees that the New Warrants will contain restrictive
legends when issued, and neither the New Warrants nor the shares of Common Stock issuable upon exercise of the New Warrants will be registered
under the Securities Act, except as provided in <B><U>Annex A</U></B> attached hereto. Also, Holder represents and warrants that it is
acquiring the New Warrants as principal for its own account and has no direct or indirect arrangement or understandings with any other
persons to distribute or regarding the distribution of the New Warrants or the New Warrant Shares (this representation is not limiting
Holder&rsquo;s right to sell the New Warrant Shares pursuant to an effective registration statement under the Securities Act or otherwise
in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.95pt">The Holder understands that
the New Warrants and the New Warrant Shares are not, and may never be, registered under the Securities Act, or the securities laws of
any state and, accordingly, each certificate, if any, representing such securities shall bear a legend substantially similar to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.95pt">&ldquo;THIS SECURITY HAS
NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED
OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR
IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the Holder&rsquo;s
exercise of the New Warrants, certificates evidencing the New Warrant Shares shall not contain any legend (including the legend set forth
above), (i) while a registration statement covering the resale of such New Warrant Shares is effective under the Securities Act, (ii)
following any sale of such New Warrant Shares pursuant to Rule 144 under the Securities Act, (iii) if such New Warrant Shares are eligible
for sale under Rule 144 (assuming cashless exercise of the New Warrants), without the requirement for the Company to be in compliance
with the current public information requirement under Rule 144 as to such New Warrant Shares and without volume or manner-of-sale restrictions,
(iv)&nbsp;if such New Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the New Warrants) and the Company is then
in compliance with the current public information requirement under Rule 144 as to such New Warrant Shares, or (v) if such legend is
not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the
staff of the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) and the earliest of clauses (i) through (v), the
&ldquo;<U>Delegend Date</U>&rdquo;)). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after
the Delegend Date if required by the Company and/or the Transfer Agent to effect the removal of the legend hereunder, or at the request
of the Holder, which opinion shall be in form and substance reasonably acceptable to the Holder. From and after the Delegend Date, such
New Warrant Shares shall be issued free of all legends, provided that, upon request of the Company (which request shall also include
a form of customary representation letter), the Holder has delivered in advance to the Company a customary representation letter that
is reasonably satisfactory to the Company and its counsel. The Company agrees that following the Delegend Date or at such time as such
legend is no longer required under this Section, it will, no later than two (2) Trading Days following the delivery by the Holder to
the Company or the Transfer Agent of a certificate representing the New Warrant Shares issued with a restrictive legend (such second
(2<SUP>nd</SUP>) Trading Day, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to the Holder a certificate
representing such shares that is free from all restrictive and other legends or, at the request of the Holder, shall credit the account
of the Holder&rsquo;s prime broker with the Depository Trust Company System as directed by the Holder. &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Holder&rsquo;s
other available remedies, the Company shall pay to a Holder, in cash, (i) as partial liquidated damages and not as a penalty, for each
$1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Warrant Shares are submitted to the Transfer
Agent) delivered for removal of the restrictive legend, $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after
such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend
and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the Holder by the Legend Removal Date a certificate
representing the New Warrant Shares free from all restrictive and other legends and (b) if after the Legend Removal Date the Holder purchases
(in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion
of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of
shares of Common Stock that the Holder anticipated receiving from the Company without any restrictive legend, then, an amount equal to
the excess of the Holder&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the
shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<U>Buy-In Price</U>&rdquo;)
over the product of (A) such number of New Warrant Shares that the Company was required to deliver to the Holder by the Legend Removal
Date and for which the Holder was required to purchase shares to timely satisfy delivery requirements, multiplied by (B) the weighted
average price at which the Holder sold that number of shares of Common Stock.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.95pt">If this offer is accepted
and the transaction documents are executed, then on or before [&#9679;] p.m., Eastern Time, on the Trading Day hereof, the Company shall
issue a press release and/or file a Current Report on Form 8-K with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
disclosing all material terms of the transactions contemplated hereunder, including this letter agreement as an exhibit thereto with the
Commission. From and after the issuance of such press release or filing of such of such Current Report on Form 8-K, as applicable, the
Company represents to you that it shall have publicly disclosed all material, non-public information delivered to you by the Company,
or any of its respective officers, directors, employees or agents in connection with the transactions contemplated hereunder. In addition,
effective upon the issuance of such press release and/or filing of such Current Report on Form 8-K, the Company acknowledges and agrees
that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its
Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and you and your Affiliates
on the other hand, shall terminate. The Company represents, warrants and covenants that, upon acceptance of this offer, and upon issuance
of the Warrant Shares, the Warrant Shares shall be issued free of any legends or restrictions on resale by Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No later than the first (1<SUP>st</SUP>)
Trading Day following the date hereof, the closing (&ldquo;<U>Closing</U>&rdquo;) shall occur at such location as the parties shall mutually
agree. Unless otherwise directed by A.G.P. (the &ldquo;<U>Placement Agent</U>&rdquo;), settlement of the Warrant Shares shall occur via
&ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company shall issue the Warrant Shares
registered in the Holder&rsquo;s name and address provided to the Company in writing and released by the Transfer Agent directly to the
account(s) at the Placement Agent identified by the Holder; upon receipt of such Warrant Shares, the Placement Agent shall promptly electronically
deliver such Warrant Shares to the Holder, and payment therefor shall concurrently be made to the Company by the Placement Agent (or its
clearing firm) by wire transfer to the Company). The date of the Closing of the exercise of the Existing Warrants shall be referred to
as the &ldquo;<U>Closing Date</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Sincerely yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>180 LIFE SCIENCES CORP.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp; </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: </TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Holder Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accepted and Agreed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Name of Holder: <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Holder</I>:
<B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Existing Warrants: <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate Warrant Exercise Price at the Amended Exercise Price being
exercised contemporaneously with signing this letter agreement:  <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Existing Warrants Beneficial Ownership Blocker:
4.99% or 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New Warrants: (200% of total Existing Warrants
being exercised): <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New Warrants Beneficial Ownership Blocker: 4.99%
or 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DTC Instructions:  <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Annex A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Representations, Warranties
and Covenants of the Company</U>. The Company hereby makes the following representations and warranties to the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. Except as set forth in the SEC Reports, the
Company owns, directly or indirectly, all of the capital stock or other equity interests of each subsidiary free and clear of any liens,
and all of the issued and outstanding shares of capital stock of each subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b) <U>SEC
Reports</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under
the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period
as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents
incorporated by reference therein &ldquo;<U>SEC Reports</U>&rdquo;). As of their respective dates, the SEC Reports complied in all material
respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading except as otherwise noted in a subsequent SEC Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c) <U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this letter agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement by
the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action
on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection
herewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by
general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d) <U>No
Conflicts</U>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of
the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&rsquo;s certificate
or articles of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or
an event that with notice or lapse of time or both would become a default) under, result in the creation of any liens, claims, security
interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give to others any
rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement,
credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such
Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which
the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company
is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result
in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations
of the Company, taken as a whole, or in its ability to perform its obligations under this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e) <U>Registration
Obligations</U>. Within thirty (30) calendar days from the Closing Date, the Company shall file with the Commission a registration statement
on Form S-1 providing for the resale of the New Warrant Shares by the holders of the New Warrants (the &ldquo;<U>Resale Registration Statement</U>&rdquo;).
The Company shall use commercially reasonable efforts to cause the Resale Registration Statement to become effective within sixty (60)
calendar days following the date of filing with the Commission (or ninety (90) calendar days following the date of filing with the Commission
in the event of a &lsquo;full review&rsquo; by the Commission) and to keep the Resale Registration Statement effective at all times until
no holder of the New Warrants owns any New Warrants or New Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">f) <U>Trading
Market</U>. The transactions contemplated under this letter agreement comply with all the rules and regulations of the Nasdaq Capital
Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">g) <U>Filings, Consents
and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make
any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in
connection with the execution, delivery and performance by the Company of this letter agreement, other than: (i) the filings
required pursuant to this letter agreement; (ii) application(s) or notice to each applicable Trading Market for the listing of the
New Warrants and New Warrant Shares for trading thereon in the time and manner required thereby, and (iii) the filing of form D with
the Commission, to the extent the Company deems such filing necessary and warranted, and such filings as are required to be made
under applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">h) <U>Listing
of Common Stock</U>. The Company agrees that if the Company applies to have the Common Stock traded on any other Trading Market, it will
then include in such application all of the New Warrant Shares, and will take such other action as is necessary to cause all of the New
Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably
necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s
reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility
of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including,
without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection
with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">i) <U>Subsequent
Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">From the date hereof until thirty (30) days after the Closing Date, neither the Company nor any
                                                             Subsidiary shall (A) file any registration statement or any amendment or supplement to any existing registration statement (other
                                                             than (x) the Resale Registration Statement referred to herein, (y) a prospectus supplement to the Registration Statement to reflect
                                                             the transactions contemplated hereby or (z) a prospectus supplement registering the issuance by the Company of shares of Common
                                                             Stock in an &ldquo;at the market&rdquo; offering, <U>provided</U>, <U>however</U>, that the Company shall not be permitted to issue
                                                             or announce the issuance or proposed issuance of any Common Stock pursuant to such &ldquo;at the market&rdquo; offering during the
                                                             thirty (30) day period provided for in this Section (i)). Notwithstanding the foregoing, this Section (h)(i) shall not apply in
                                                             respect of an Exempt Issuance. &ldquo;<U>Exempt Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to
                                                             employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of
                                                             the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established
                                                             for such purpose for services rendered to the Company, (b) the shares of Common Stock issuable upon the exercise or exchange of or
                                                             conversion of any securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of
                                                             Common Stock issued and outstanding on the date of this letter agreement, provided that such securities have not been amended since
                                                             the date of this letter agreement to increase the number of such securities or to decrease the exercise price, exchange price or
                                                             conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such
                                                             securities, (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested
                                                             directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144)
                                                             and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the
                                                             prohibition period this Section (h)(i), and provided that any such issuance shall only be to a Person (or to the equityholders of a
                                                             Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with
                                                             the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall
                                                             not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity
                                                             whose primary business is investing in securities, <FONT>(d) restricted securities for settlement
                                                             of debt and for investor relations services, (e) securities for repricing of warrants for non-Armistice warrants up to 30,000 shares
                                                             and/or warrants,</FONT> and (f) any securities pursuant to transactions that qualify as &ldquo;exempt issuances&rdquo; that are as
                                                             defined and permitted pursuant to any currently outstanding agreements of the Company. &ldquo;<U>Person</U>&rdquo; means an
                                                             individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
                                                             joint stock company, government (or an agency or subdivision thereof) or other entity of any kind, for purposes of this Section
                                                             (h)(i).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">From the date hereof until one (1) month following the Closing Date, the Company shall be prohibited
from effecting or entering into an agreement to effect any issuance by the Company nor any Subsidiary of Common Stock or Common Stock
Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo;
means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or
exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or
exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock
at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is
subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified
or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into,
or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;,
whereby the Company may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have actually
been issued and regardless of whether such agreement is subsequently canceled; <U>provided</U>,&nbsp;<U>however</U>, that, following the&nbsp;30<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT>&nbsp;day
anniversary of the Closing Date, the entry into and/or issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering shall
not be deemed a Variable Rate Transaction&nbsp;. The Holder shall be entitled to obtain injunctive relief against the Company to preclude
any such issuance, which remedy shall be in addition to any right to collect damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">j)</TD><TD STYLE="text-align: justify"><U>Form D; Blue Sky Filings</U>. If required, the Company agrees to timely file a Form D with respect
to the New Warrants and New Warrant Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any
Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for,
or to qualify the New Warrants and New Warrant Shares for, sale to the Holder at Closing under applicable securities or &ldquo;Blue Sky&rdquo;
laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Holder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">k)</TD><TD STYLE="text-align: justify"><U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth in the
SEC Reports, which also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as
of the date hereof. Since the Company&rsquo;s most recently filed quarterly report under the Exchange Act on August 12, 2024, the Company
has not issued any capital stock, other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option
plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans, and pursuant
to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under
the Exchange Act, or as otherwise set forth in the SEC Reports. No Person has any right of first refusal, preemptive right, right of participation,
or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth in the SEC Reports,
there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or
capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares
of Common Stock or other securities to any Person (other than the Purchasers and the Placement Agent) and will not result in a right of
any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities, except as set
forth in the designation of the Company&rsquo;s Series B Convertible Preferred Stock, and adjustments to the number of shares of common
stock issuable upon conversion of such Series B Convertible Preferred Stock. There are no outstanding securities or instruments of the
Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument
upon an issuance of securities by the Company or any Subsidiary, except for the Company&rsquo;s Series B Convertible Preferred Stock.
There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound
to redeem a security of the Company or such Subsidiary. Other than as disclosed in the SEC Reports, the Company does not have any stock
appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares
of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with
all applicable federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights
or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors
or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar
agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between
or among any of the Company&rsquo;s stockholders. For purposes hereof, &ldquo;<U>Common Stock Equivalents</U>&rdquo; means any securities
of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation,
any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable
for, or otherwise entitles the holder thereof to receive, Common Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">l)</TD><TD STYLE="text-align: justify"><U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest
audited financial statements included within the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence
or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred
any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business
consistent with past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to
GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has
not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements
to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director
or Affiliate, except pursuant to existing Company stock incentive plans. The Company does not have pending before the Commission any request
for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in
the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to
occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets
or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation
is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.
For purposes hereof, &ldquo;<U>Material Adverse Effect</U>&rdquo; means (i) a material adverse effect on the legality, validity or enforceability
of the Transaction Documents, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial
or otherwise) of the Company and the subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability
to perform in any material respect on a timely basis its obligations under any Transaction Document.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">m)</TD><TD STYLE="text-align: justify"><U>Registration Rights</U>. Except as set forth in the SEC Reports, no Person has any right to cause the
Company or any subsidiary to effect the registration under the Securities Act, of any securities of the Company or any subsidiary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">n)</TD><TD STYLE="text-align: justify"><U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b)
or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect
of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission
is contemplating terminating such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding
the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that
the Company is not in compliance with the listing or maintenance requirements of such Trading Market. Except as set forth in the SEC Reports,
the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in material compliance with all
such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust
Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company
(or such other established clearing corporation) in connection with such electronic transfer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">o)</TD><TD STYLE="text-align: justify"><U>Solvency</U>. Based on the consolidated financial condition of the Company, after giving effect to
the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s
assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital
to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all
of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of
its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts
as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge
of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the closing of the Inducement Offer. The in the SEC Reports set forth all outstanding secured
and unsecured Indebtedness of the Company or any subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes
hereof, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than
trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations
in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet
(or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in
the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be
capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TO: 180 LIFE SCIENCES CORP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby elects
to purchase the number of Warrant Shares of the Company pursuant to the terms of the Existing Warrant set forth below and tenders herewith
payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Holder: <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Holder</I>:
<B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U STYLE="text-decoration: none">&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Existing Warrants Exercised: <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U STYLE="text-decoration: none">&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amended Exercise Price: __________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate Warrant Exercise Price at the Amended Exercise Price being
exercised contemporaneously with signing this letter agreement: <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Existing Warrants Beneficial Ownership Blocker:
4.99% or 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New Warrants: (200% of total Existing Warrants
being exercised): <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New Warrants Beneficial Ownership Blocker: 4.99%
or 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DTC Instructions: <B>_________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FORM OF NEW WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(See Attachment)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ea021778501ex10-2_180life.htm
<DESCRIPTION>FINANCIAL ADVISORY AGREEMENT, DATED AS OF OCTOBER 16, 2024, BETWEEN A.G.P./ALLIANCE GLOBAL PARTNERS AND THE COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 112.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 112.5pt 0pt 0">October 16, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 326.7pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 326.7pt 0pt 0"><B><U>CONFIDENTIAL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 326.7pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">180 Life Sciences Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3000 El Camino Real</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Building 4 Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Palo Alto, CA 94306</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention:&nbsp; Mr. Blair Jordan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>Re:</B></TD><TD STYLE="text-align: justify"><B><U>180 Life Sciences Corp. &ndash; Financial Advisory Agreement</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Jordan,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of this letter (this &ldquo;<B>Agreement</B>&rdquo;) is to confirm the engagement of A.G.P./Alliance Global Partners (&ldquo;<B>A.G.P.</B>&rdquo;)
by 180 Life Sciences Corp., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), to render Financial Services (as defined below)
to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><U>Services</U>. During the term of this Agreement, A.G.P. shall, on an exclusive basis, provide advice
to, and consult with, the Company concerning, any private or public equity or debt financing involving the purchaser identified on <U>Exhibit
A</U> of this letter or any &ldquo;affiliate&rdquo; (as such term is defined in Rule 405 of the Securities Act of 1933, as amended the
&ldquo;<B>Securities Act</B>&rdquo;) of the purchaser identified on <U>Exhibit A</U>, and such other, similar matters as the parties may
mutually agree (collectively, the &ldquo;<B>Financial Services</B>&rdquo;). The Financial Services shall be provided to the Company in
such form, manner and place as the parties mutually agree. Examples of such financial services may include, without limitation:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">Any private or public equity or debt financing including a warrant inducement transaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify">providing introductions to or strategic advice with respect to potential investors or other sources of
capital to finance the Company&rsquo;s business objectives;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iii.</TD><TD STYLE="text-align: justify">providing other general corporate finance or strategic financial consultancy services as required by the
Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iv.</TD><TD STYLE="text-align: justify">providing consultancy services in connection with capital raising, recapitalization, or restructuring
by the Company, including, raising capital by means of senior secured debt, unsecured or subordinated debt, preferred stock or common
equity; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">v.</TD><TD STYLE="text-align: justify">additional services incidental to the above, as directed by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>Term</U>. The term of this Agreement shall be a period commencing on the date of this Agreement and
continuing until the earlier of (1) the closing of the Armistice inducement transaction,
or (2) December 31, 2024, unless sooner terminated by the Company as provided herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><U>Compensation</U>. In consideration of A.G.P.&rsquo;s entering into this Agreement, as compensation,
in full, for the Financial Services, the Company shall pay to A.G.P. a cash fee equal to $232,000, which shall be payable by wire transfer
in immediately available funds to A.G.P.&rsquo;s account set forth in <U>Exhibit B</U> of this letter (the &ldquo;<B>Financial Advisory
Fee</B>&rdquo;) on the closing date of the offering. For the avoidance of doubt, it is clarified that the foregoing is the sole compensation
to be paid to A.G.P. for the Financial Services.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><U>Expenses</U>. In addition to any fees payable to A.G.P. hereunder, the Company hereby agrees to reimburse
A.G.P. for accountable legal expenses incurred by A.G.P. in connection with the Financial Services in the amount of $65,000 as well as
non-accountable expenses (the &ldquo;NAE&rdquo;) including, but not limited to, IPREO software related expenses, background check(s), marketing
related expenses; i.e. roadshow, travel, et al. and any other expenses incurred by A.G.P. in connection with the Offering (with roadshow,
travel and marketing expenses requiring preapproval of the Company, acting reasonably), (provided, however, that such reimbursement amount
in no way limits or impairs the indemnification and contribution provisions of this Agreement). The total NAE allowance shall not exceed
$10,000.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><U>Tail Fee</U>. A.G.P. shall be entitled to compensation under clauses (3) and (4) hereunder, calculated
in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any
kind (each, a &ldquo;Tail Financing&rdquo;) to the extent that such financing is both (i) provided to the Company by investors that were,
during the Term and prior to the earlier of A.G.P.&rsquo;s receipt of a termination notice under Section B hereof and end of the Term,
contacted by A.G.P. or contacted A.G.P. and (ii) such Tail Financing is consummated at any time within the 6-month period following the
expiration or termination of this Agreement. Notwithstanding anything to the contrary herein, the compensation due hereunder shall expressly
not include any stock or equity of the Company issued to its officers, directors, employees, consultants.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Termination</U>. This Agreement may be terminated by the Company at any
time after 10-days written notice to A.G.P. Upon the termination of this Agreement, no further payments will be due or payable to A.G.P.
Notice required to be given in writing pursuant to any of the provisions of this Agreement shall be (a) sent via electronic mail, if to
A.G.P. at thiggins@allianceg.com or, if to the Company, to Blair Jordan, Interim Chief Executive Officer, at </FONT><U>blair.jordan@highmontadvisors.com</U>
<FONT STYLE="font-size: 10pt">or (b) mailed by next-day delivery using a nationally-recognized overnight courier or hand-delivered (a)
if to the Company, at the address set forth above, and (b) if to A.G.P., at 590 Madison Avenue, 28<SUP>th</SUP> Floor, New&nbsp;York,
New York 10022, Attention: Thomas Higgins.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><U>Amendment</U>. No amendment to this Agreement shall be valid unless such amendment is in writing and
is signed by authorized representatives of all the parties to this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><U>Waiver</U>. Any of the terms and conditions of this Agreement may be waived at any time and from time
to time in writing by the party entitled to the benefit thereof, but a waiver in one instance shall not be deemed to constitute a waiver
in any other instance. A failure to enforce any provision of this Agreement shall not operate as a waiver of this provision or of any
other provision hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><U>Severability</U>. In the event that any provision of this Agreement shall be held to be invalid, illegal,
or unenforceable in any circumstances, the remaining provisions shall nevertheless remain in full force and effect and shall be construed
as if the unenforceable portion or portions were deleted.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Indemnity</U>. To the extent permitted by law, the Company will indemnify
A.G.P. and its affiliates, stockholders, directors, officers, employees, members and controlling persons (within the meaning of Section
15 of the Securities Act or Section 20 of the Exchange Act) against all losses, claims, damages, expenses and liabilities, as the same
are incurred (including the reasonable fees and expenses of counsel), relating to or arising out of its activities hereunder or pursuant
to this Agreement, except to the extent that any losses, claims, damages, expenses or liabilities (or actions in respect thereof) are
found in a final judgment (not subject to appeal) by a court of law to have resulted primarily and directly from A.G.P.&rsquo;s fraud,
willful misconduct or gross negligence in performing the services described herein.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">Promptly after receipt by A.G.P. of notice of any claim or the commencement of any action or proceeding
with respect to which A.G.P. is entitled to indemnity hereunder, A.G.P. will notify the Company in writing of such claim or of the commencement
of such action or proceeding, but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder,
except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses. If the Company
so elects or is requested by A.G.P., the Company will assume the defense of such action or proceeding and will employ counsel reasonably
satisfactory to A.G.P. and will pay the fees and expenses of such counsel. Notwithstanding the preceding sentence, A.G.P. will be entitled
to employ counsel separate from counsel for the Company and from any other party in such action if counsel for A.G.P. reasonably determines
that it would be inappropriate under the applicable rules of professional responsibility for the same counsel to represent both the Company
and A.G.P. In such event, the reasonable fees and disbursements of no more than one such separate counsel will be paid by the Company,
in addition to local counsel. The Company will have the exclusive right to settle the claim or proceeding provided that the Company will
not settle any such claim, action or proceeding without the prior written consent of A.G.P., which will not be unreasonably withheld.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Company agrees to notify A.G.P. promptly
of the assertion against it or any other person of any claim or the commencement of any action or proceeding relating to a transaction
and/or the services contemplated by this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iii.</TD><TD STYLE="text-align: justify">If for any reason the foregoing indemnity is unavailable to A.G.P. or insufficient to hold A.G.P. harmless,
then the Company shall contribute to the amount paid or payable by A.G.P. as a result of such losses, claims, damages or liabilities in
such proportion as is appropriate to reflect not only the relative benefits received by the Company on the one hand and A.G.P. on the
other, but also the relative fault of the Company on the one hand and A.G.P. on the other that resulted in such losses, claims, damages
or liabilities, as well as any relevant equitable considerations. The amounts paid or payable by a party in respect of losses, claims,
damages and liabilities referred to above shall be deemed to include any legal or other fees and expenses incurred in defending any litigation,
proceeding or other action or claim. Notwithstanding the provisions hereof, A.G.P.&rsquo;s share of the liability hereunder shall not
be in excess of the amount of fees actually received, or to be received, by A.G.P. under this Agreement (excluding any amounts received
as reimbursement of expenses incurred by A.G.P.).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iv.</TD><TD STYLE="text-align: justify">These indemnification provisions shall remain in full force and effect whether or not the transaction
and/or services contemplated by this Agreement is completed and shall survive the termination of this Agreement, and shall be in addition
to any liability that the Company might otherwise have to any indemnified party under this Agreement or otherwise.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company represents that it is free to enter into this engagement letter and the transactions
                                            contemplated hereby, that it will act in good faith, and that it will not hinder A.G.P.&rsquo;s
                                            efforts hereunder. Notwithstanding any provision of this engagement letter to the contrary,
                                            the Company agrees that neither A.G.P. nor its affiliates, and the respective officers, directors,
                                            employees, agents and representatives of A.G.P., its affiliates and each other person, if
                                            any, controlling A.G.P. or any of its affiliates, will have any liability (whether direct
                                            or indirect, in contract or tort or otherwise) to the Company for or in connection with the
                                            engagement and transaction described herein except for any such liability for losses, claims,
                                            damages or liabilities incurred by us that are finally judicially determined to have resulted
                                            from the bad faith or gross negligence of such individuals or entities. A.G.P. will act under
                                            this engagement letter as an independent contractor with duties to the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify"><U>Governing Law and Arbitration</U>. The validity, interpretation and construction of this Agreement
and each part thereof will be governed by the laws of the State of New York, without giving effect to its conflict of law principles or
rules that would defer to the laws of another jurisdiction. If a dispute or claim shall arise with respect to any of the terms or provisions
of this Agreement, or with respect to the performance by any of the parties under this Agreement, including but not limited to securities
activity and financing advice, then the parties agree to submit the dispute to binding and non-appealable arbitration in a venue located
in New York, New York, in accordance with the Code of Arbitration Procedure published by FINRA Dispute Resolution. The determination of
the arbitrator shall be conclusive, final and binding on the parties. The prevailing party shall be reimbursed by the non-prevailing party
for all reasonable attorney&rsquo;s fees and costs (including all arbitration costs) incurred by the prevailing party in resolving such
dispute. Any award rendered in arbitration may be enforced in any court of competent jurisdiction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify"><U>Counterparts; Facsimile</U>. This agreement may be executed in any number of counterparts, each of
which may be deemed an original and all of which together will constitute one and the same instrument. A pdf or facsimile signature of
any party shall be considered to have the same binding legal effect as an original signature.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify"><U>Entire Agreement</U>. This Agreement contains the entire agreement between the parties with respect
to the Financial Services and supersedes any and all prior or contemporaneous written or oral agreements relating to any Financial Services.
Neither party is relying on any agreement, representation, warranty, or other understanding not expressly stated herein with respect to
the Financial Services.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In acknowledgment that the
foregoing correctly sets forth the understanding reached by A.G.P. and the Company, please sign and return to us one copy of this engagement
letter. This engagement letter may be executed in counterparts (including facsimile or .pdf counterparts), each of which shall be deemed
an original but all of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Yours truly,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>A.G.P./ALLIANCE GLOBAL PARTNERS</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ Thomas J. Higgins</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Thomas J. Higgins</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Managing Director</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Accepted and agreed to as of</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">the date first written above:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>180 LIFE SCIENCES CORP. </B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ Blair Jordan</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Blair Jordan</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Interim Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Armistice Capital Master Fund Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Wire Instructions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>atnf-20241016.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /K4ps7xRiXgen8uGZHRMOayJiaP9wpV76ZkxvWR1HZmKTy0kId/F6yao79nGQaMP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ATNF="http://180lifesciences.com/20241016" elementFormDefault="qualified" targetNamespace="http://180lifesciences.com/20241016">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://180lifesciences.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20241016_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20241016_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20241016_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="ATNF_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>atnf-20241016_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20241016.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnf-20241016.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnf-20241016.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>atnf-20241016_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20241016.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_CommonStockParValue0.0001PerShareMember" xlink:to="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20241016.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>atnf-20241016_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20241016.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnf-20241016.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnf-20241016.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45394344882032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 16, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 16,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">180 LIFE SCIENCES CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-1890354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bldg. 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Alto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">507-0669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase shares of Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNFW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-\#W*RG-VXG=ERRVE4=_ U!+ P04    " ! <5!9X/0ZB:H"   P#   #0
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 0'%0614GP77O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 0'%0
M69E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " ! <5!9BMU7=,X$  !B%@  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 0'%0
M6>#T.HFJ @  , P   T              ( !$@T  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " ! <5!9EXJ[',     3 @  "P              @ 'G#P
M7W)E;',O+G)E;'-02P$"% ,4    " ! <5!9JL0B%C,!   B @  #P
M        @ '0$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 0'%0620>
MFZ*M    ^ $  !H              ( !,!(  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 0'%06660>9(9 0  SP,  !,
M     ( !%1,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&7Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0217785-8k_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://180lifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnf-20241016.xsd</File>
    <File>atnf-20241016_def.xml</File>
    <File>atnf-20241016_lab.xml</File>
    <File>atnf-20241016_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0217785-8k_180life.htm">ea0217785-8k_180life.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0217785-8k_180life.htm": {
   "nsprefix": "ATNF",
   "nsuri": "http://180lifesciences.com/20241016",
   "dts": {
    "schema": {
     "local": [
      "atnf-20241016.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "atnf-20241016_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnf-20241016_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnf-20241016_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0217785-8k_180life.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://180lifesciences.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-10-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0217785-8k_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-10-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0217785-8k_180life.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "auth_ref": []
    },
    "ATNF_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20241016",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20241016",
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-24-088119-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-088119-xbrl.zip
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MD1"(*7G+KT/AKW3Z&"'1P630EDIS1 EWMGZ@,?(<&PC8V;W(P".Q?[+D#[T
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MN>K\H1R?UFJ7\ L1(]GL SL72C<XU9N8*=X$4WPXM*(R[_2(WJ7*#0.9@SG
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MB"*5BI770^G9Q6,].4Y:[7,?!=>F)K?/F(9"5,#S[&SVV%+'Z$>QJ'&CSFL
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MY2V)F,SS%/C2H+8+V4CP%\]W#ST_\3OTM*6T)\AL>B*SR946N<T=<SQ=I49
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M@1KT8A%.!\$R/L-Z-57%3NI'UX@Q,M?N>!P$8%,+<Z7?1Z(MCZE#$] >S,@
M+^L9$-N@'JZ$\"S ],#?4A6DP%G)=S+$MR"H69@:3BSG%B&HU-8]:F1"X?I
M'$)-!9>*,8QH; L"^-\BM$&$5L,A$>_$)L]RKB0MDF<13RTUXW;PH1$A]VGH
MD%-AA\PW(H<M#B:B[KCW'61\GA.*D](@A3AUM*GNB@4/S(PHN8AW/X!UXBAJ
M:)7UWICK0<9OXMJ&[KF9E/@$0MW#UTB(%@[C6Z/G5Z1QD^OJH"W@<?B0 %A8
M==_GA&?++3'N/\>N&9Y+^\BINJ..1^(]CC ,CTXHZ0.S*,X*A#JDL9E%C0OF
M%QO)XC5NGB%LK5])R,2'W>'NPF*#>FF<.G2$*U*<>?,8(9/BM1F8M= YY ',
M82;<"@]$?-1$PL_%:%[+&%(N%N%JQ(IG"P?AP%YK[HA"U C;K]^Z_4#W, *?
MB^N70CY7JB9100@4&+3, %E'#?4# 2YB"&=)S.:P<"R\1-QW /@1Y2)L8S*$
M[T_W17(@RD#,Q\L28A3 R_B2I-+ J2WJ11O-2P]< N@JCZ Q9F):RO<O"P7B
MHX4-S8YG#<2N$AXAZD*G(6:$(=UW8J[H44DQ5ZG\@;I0P3\RN*]D0:_,YJPX
M)9"$^(DO^?+;'$+23_N8SJQ0)\PX/B:? &@A>E)<N,%Y.NY0MW$;C,8P90WV
MNL15+O"YFXHAQ&^WN0ZAS4N/R@%IV=Q+["->_KK] >%[B%]N9?+A-'KT&F;T
MC9MB_@<$7RNR3VH.[>EJ\!).I-&%A3.7(RN.02^^LOY/70O]1^I!) ,Q!T M
MC=1RI[G+7+YF@,U$IIX:5@^\]B5U/#1-VQ<4!,"XFJ78(8,6V1B[F'TNROHN
M<^[P!K"810N>7D:2('<\ M+H]X ][5D\]M4RD7TW%$0B %T+5@P6]:H>\R:,
MF9&D%[VH0#T3DP"+)RF:L!+!8VVEH&0D25J*'"?,C\\-UPH!=9@^Z@'&S ?-
M$R;NOL3F(N[&(3N'@>9+&Q':+$HBFZNS083 (WA3C2^BS5=P_ETN\7F\(<%]
MDYJ$AFU@(:$UYJJ.;OM91O("9&:]6 9LBK!%LW@$Q]-CQ_-7'/EN->9QR4]A
MLH4E_OE+)P"&[O" S\%:&T11\U?I+@)T+&'!C!=W1XEB>6Q]UT_H>8,@\EI=
M^$@M171^Y,B302P/:Q@ ;;%^/M1[J!"RE).7+@=^0'?HI?B]./H/[E@,C0:3
MLD75SYAE!.D@3*N/'0>IXK^>)ZAM[V4_I7 D?7Y3.F910';@2)@%O_6*JT\H
M4?7UIS>G5XI;3)&X@)D.K;O%W=D4WOHM ON1V.GYJ&6!*-R531O(X2 [ T6$
M. \YSGW4E:DCRWG-&)#HN8R_I"E43K;PNK9PG@:F>\3-QF)U/-+!8;S2QJLE
M+RXWKRL>T66A>3J62BY)/< 1HF-_J$@]%;V??B.EOYVND),4$+K05#I ,>Z
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M3<>XXH0@8,A9"C)L3.&&<3R+IZ**HK:,6<AJGN1Q5@-;IS3J&$7A#]L1@N4
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MF%9BI"MOAO05YR]=9]$JP\$G*H,&%J1M62PP4WC]/B^N0+&?)@$E@FF8U%=
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MSR#&1WO'![]C%MFCU^=OW[S\_U!+ P04    " ! <5!9N]@0#.$9  #5@@
M'0   &5A,#(Q-S<X-3 Q97@Q,"TR7S$X,&QI9F4N:'1M[5UK;QM'LOTN0/^A
M5]@;2 !%O6PGL11AJ8<3+619D.@-@HO[H3G30W8\G&&F9R1S?_VM1W=/#SFT
M*%N,\U" 74OD3#^K3E6=JFX=_=1_>WF\OG;TTWGO#/X5^-]1_Z)_>7Y\M,/_
MPK<[]NNCDW=GOXC;_B^7YS]L)'E6OA9[NY-2]/58&7&E[L5-/I99AS_HB%M5
MZ&0#7H17KQ_[WJ$HU<=R6Z9ZF+T6A1Z.RD,QEL509]ME/GDMH 7_P2 ORWS<
M_"Q524F?;!P?G1R??QSI@2ZAX^[^T<X)3._ZLP?&'5#;8F]OO_L2_L6?=S>.
MO\D&9G*XHL;?164^4(78>]41^[O[+YZJFX/]5]UOZVY@M=PTGFZ=YOLX>G]\
M^N[JS<79^57_HG=YM//^>+4=/OVDH-V][W;%I4Z4N(VTRB)X\S0O)MTG[.%@
M=W=7G*?B5(YUEHL;)=,G;/VDTFFLLZ%X(6XK72H0K-TG;/Y:IKGHI67>$:<]
M\?V+@]U73]AZKRQ55NH\>\U[*]X677&22EV(?^=%++,G[&M&L_N]D\MS<7I^
M>7G=.SN[N/KQAXW=#?K]]KIWZG[_S$X? +A['9<C;&_W?T"P^S>NFSM5E#J2
MJ0--:*6)HK]6IM3)%"'YJ'_F7K/-[>IL U'_[+CEN^[^2YTU&T-\);VZ4:]9
MJ9JOMG;,>K] :<0W62S-Z%"\T9G,(BU3T8OOM,F+J>@-"Z7&L-LU3O3))NWT
M;_!GW(X5;?67-WBF9$&RR5+969U8?FF#K?)B/]19K+#1W>Y+%)7^2(E)54QR
MHT2>B'*D#<@$:&0A-NF7;]+XMRH_A"T/-@]@N*"/MP0\4N8BRK-$%V-X7PF5
M#>60'L06>]T?N]?=G5Z::I &)7Y,\P&(Q+4LRDP51FP&'="C8>OK:X.I6"!G
M'2'%F4KEO2P4] ]3*"2B"(Y;!<,^S<<3F4W#9CLXY$+!2A2!E,)*WFEL?E,:
M$:M$9RH6 Y7F]S .> &;M8T]G658H-J?A5,_7YSU?_IA@Q!E):#U$$XM@"26
MM(6@1-_N=9=#GO?';IL00KKBK"K0[N'>@,R.O0Q[8>U8"11F)-.T(T! 9";4
MQRBMC+Y38B"-AD68%/F=CI60,3:.^PWRE<4HV*9*2T#K<M0)10"_B5210>_X
MY!1:T'<23&]>@$(-4AT)]1O8XBE^$*M!*1*6-!BMSN[R],Z-&]0O&DD#LJA1
M-76B0>Y@F#!7Z^^NK_5PMK,*"@UCQU;499)HT+%262DG,395-.*%T;5,ZTS<
M5*D2+W9?<I.@6BJ"A2PU"$@O(KW=^_[@ "9FA!RCHL3XV/I:K5;--QJ08-M\
M>%Z"IL4+32/-X;VB(XP>ZQ3 =BQQG@9'00T"9F!_8SE=7QM7904;.A42=UIL
M1GF:JJB$+4VGO%'U6.=U/!QO5R (MN  20P@@!..6#11 !9R?8W&G>3%N /C
MR@#2:#:35 +6S8Z[,>2N./\HQY,4OH %XV;\&(P; \P5N@%AC56'A#"O2I'"
M^I0$=J]9:Q:;SZ5<D>6CP+\2+NT]C$IZ.53J/5;]<3_Q)RG >A42+"68Y2IB
MHUG"!T9&N+V'#VWO9UH=CDN[<][@7]+^++//2VXT P'O85GDL&6X2^0!P38;
MV+E2#6'KV8J0OH*?828 3/C,)*=(!_0;+( R90[8!N\1Z@F3 UX2&*RO17("
M"I[B.RPV*L2=;PJ#P&7$ $Q8I@R\,_B5L<\\2\SO)3&/%AG>YJ$"&P%;ZSQ6
MY7>X(4&U*; >"/PVK<T"6)8"\:5 %W7*MME*QZHDX'G?:=_O'KOMK?L'+AA\
MGBG"#\8)I_.%U(:<RD+9C_1_R=9W4$( 3<H"8(?<7@J/ F#HU*:EX]KQ[<*C
M8P66A;P-E6D4-_3A0(+0/G5$E;G?\:MJ %$N"&'IOY\4*E$%?@_(%7W IZ)\
M/,[!"6)3=XBNSRKQQ^[!WTSDEI0X&<<:Q23T'D$<R/=F4X*2(@?YG2*_/@;P
MB$J/'T%HNY(-7 $AXYOZQ_8V^.\JC5^+:SE4A_#\;Q52!="LV-ZV.9&CLXO_
MM+G%>_LM&_H*/T,54(7_[ 2<^@]H!*%[DZ<ZAB%<M^U)!$NNBB6EIEZ6HQT8
M8<M@!X62'[8'"J(,F-&$9A@V_:JE:9Q4.+Q@Z19V&2SC#JXC+]W7XUW_H"J[
M%)^QOS2?T8?HG+F,_D(2HPY%I9C ]/*8H%=Q/ $6!!4XIO!C[E7 9' H8=ET
M5N'3%?R4,E$GBU0CCY"(S;TM^BA*<S(:-H3O%6,-(P7GI#T^Z:RO@178W-\2
M9PJ^Q;36P1ZGM=">I.B;FCS'J!@G9LU)$W 0BWR #1Z2TMF#&/0<U7Z9=!XL
M+9VX20JV&W>;I?2"7!<#VV7Y5D_R^KB$X,]&2?D<'P?['06M@@R!-Y142,X!
MPI%HS),Q3>Z-U6$BIVC6++\GP=,Q(Y$HA9$W6[Q_[A_L=W9W=SOB?J2C4<#H
MR*D<I I%\1[L(,LT>#<T%@V:%2.3AE3-G=0I/9I466SJ_OQD913E%:JH*G'\
MX,GI!L=UTD;=;2XBJ%RJ9'WMC5)-5BUK:&BM[?A/0NO=%6_L LJ[7,<<520B
MSBOTWV L,( HE053<>5(EO0PVI5A3OO%A!48-]78(^*_:=ET'"SYXNUZUN 5
M:_"+I37X_"-NH^/+07N=HX@;B<H$&F.\0M2;BU!<88JDJ7KX\<!2F(;S*'H\
MJ H#$6@@%E8KJ,U4#4$TE!T'.J5580-7^T9+.-0N5_@DR?>8= Z$^Y^O7J*&
M(ZK<*U!N:=;7LCS;#@?@NP[5[JIW7B>QZK!I4)4BRRW'2I1O1UQ<WYR_ ZU(
M2DHV%2HE.^::A9? ,1P6T!_8Y9&*/FR:+:2#BP^JI#!M]HU#H;NJ*XI<QF:4
MWW<0?^X4 "!@B$R[1"'C8C-E\!DK]\XB@MAD#LIU!(I,/5$/?H!U#TPJX$<0
M[<D)VF58?0LS/LI$XP^/P!,&XHU!.H79;CH;WA'0D;ICN0&$(6;;"PF[)+1[
MA+59+NX!QFFUB0S3T(<N&(<P5SG. *TBMC0V(5,6&G8)/Z ^#5%P<XZ/Y?7+
M'*,?V&Q8V#2_)TQD,X"[K#Y&2H%_],^]792B9]A:,6R]7-XM!KLKR 8B;(4Y
M/#1$2*.6*6=D0D,E"+'0R%6D[P=;)#2;+[9"/(/I1!5I),D@BIK-W=1&O&17
MM#-'XE*NCQE^Y/H=[>\4SO.Y-=^/1 F3,-N.E E\:)1<:'-][8/&D2H9C3"U
M;5&*E\$UY0'+1O.P=N21>ST+D@P&PE<8^:;>6IB_&DP#(IH:N8=) TC$=585
MPQ-.:15(&;F.Z]!AQATJ(!#0$X)FZ9U^G":H&P82O$&W%K!.:%MH!0 =X7\6
M:K#7#H<MTI$45@:(=G(?.]\/5T[#3&D1FFM&3@]R<.,Q8; L:0M+T K:6RL
MK[;'T.K(A5=)CFAA%V%]#0!2.W>W:$QK#G>ZXBHOL6%3PK HRY--L9NA6SR"
M,%E,A1,Q_C"0XKA2M;Q:J8<A@!2:=(KVK71)09J+Y^-<RJF!U[  IN+-)XQ-
M $]5 8C #%"./ZKQ),VG"G'"\Y7ELQ>W:C@\>O/NJA\.>MOH_RH>^<;Q*UA_
M?&#)HJQ/MF6)!BNUCF]H$ 68:AZH3P7J)0,5J8Y,,([9V]V.Y11<KT)C%9]3
M\MJ+?#^Q<<LG=::#?D!2%02<X(KB9]"H9K!';<B+>1=U?>V*N_.I$(Y2AOH.
MA@)ZC:,B7P8\CPJSK!:^78'")[R'VM1LRBWDRTMQIZ506&-0Y!F _QA0!H(J
M>#'WGB\%5'H( F3^)6W%T[ +J@WCM\\V/2GX/:QT!%>30N>Q.!UIE8CSCRJJ
M,*^'#AUJ;0>[<%+Q_GB [W9_I7?_!1V/$,,DAY &^\6-!NG\I&@@@S/8HOGP
MGF<H7K"M(E8I] U 51G.5O/^80W#-D!'/LR@&<#L.ZR#&8Y*P XP'%R9,@+P
MV[8-P#.PBF!KYQ? AJ 0DQ1$%GG[ZXAJ1'88';_*RTQOO?Q^5[R5,<PT$SW8
M[PH>WO_NZ/;]]7$Y.MK!?\6;-,=U!^5G9/DE+SZ 54$PP!^Q]G)_OR/J E10
M"0 )(W[B/6SJWS,,K@H&OUW:*^QA,9(K($5+R^5)S$O.4DVU#D,0HV-/2**/
M4+^F30@5Q);"1P:Z9FV053G*"Q+T0J$)QGP*Y=K)QTG31HW/W""^L@W];.K^
M(5E8(O>R?RC>3:A XC7V9GV^0_$?F5;X]>^5FOF\PRJ/2N*$R^ 6X%#TIQ.8
M9Z^0 QT=BBN0.5XD$%N8^GXCX>+>PF_^FLF@I?-@?Q/4^VYIU/M9HA6UD7#M
MOZ!+91PIPIQ>FR=C_;I[;*09_N"K20'>"?[&-<[X<0"'U@-$=)LV@F[\=* R
ME>B20^4\8>Y,<D<%MI)GV!C&00W2!5TZ')N-WN$!75:E\J]24%[37ZX%F+M(
MP$FI"O(!508J$"E;>VL]N86.'/:;3Q05W&!1JQNE>SYHH? 1.?=??\7S?(Z*
M5JP8WS^B%AQZ!G1-(>KU_#;Q$W>>%UE./@88<*<N@M 9>0S@LJ=$7G.>L\JL
MS%$88F4TTD54C5E";9:J4.!+9TRB^@C#BB$.&)XA1X2?$S;[)9PXQT(E"9)-
M5!;M1D=Z4E1(68'\:D: YH@FX#A;";8_&B)TT(]7$,\]"^ZJ#S'L+BFY#X7J
M%TQ\.Z'N-]B^"4;2I8W/4WG?S,]0T.R(\VD=F8(L(?OC3PG FA%M-,K3>)8-
MJBFB@!<:4W[?U"1\#@$NRCA\B)*V&9!I6&AFRPBLU[>^MK?PL$%-!^[ONF?.
M/T8008+; 4]L"3F4: 7(VTYS0SF7"&+?,8Y;CL$]P;&Z) :.$.9(L*#Q&UN'
M;R1:.<S@^$3*9EV+S9IK,QJ*LV*DC*Y9&!FFE(Q*MSJ< [*<'J:["N9UL3H?
MGJ.5QH)<GF5-Y5%U.),1]DQ1DP;!?,2D;*-W<6\?GCJT'\Q<;%(FCI$ ML:S
MV&S(8%T+6)"$\E8(9T0?IR"G\9"@<1.MIJFHN)BXD\E$R72+HB**]6FR((+X
MY4C>X0(B=ZB(+0;5TYA!A\99MN 7\C9F&..DD%4,"(N2"T HQMJ@/U.Q: P+
MF#3@YA!TB/QC&"B(')ZX<+OFR]UB9:)"#\(ZDN?X_8]R2.(:MGZ",L#,H<L3
M!,1^XNA#]K]8S(6M,;#U3OY<(1&2D;=W18Z)/$JVSB9LN/3#Y4M-PXW5#FC#
M])!]E) 41Y0T:=# /78'=_Q(+7J%@P77P3[5-EQVF@.WUN1M?=9.+ "/!B>B
M\2UI%3G, UATYE@U._ZDE?7<,)-!"(-:F6?I= 9J.(ED1\/*['/NH'*) D^]
M4+/$,$UP@#X0'6Z@:QX8/&.5$#"!8];(2:ROP3R)3.6D+V>>E6FD>EH,FS2F
M&O/D;=/B4ZM+8Z 7V9 Y  ]2US 26#"32+1]C7HB]RJ5&8T66 3>?FYU/O/#
M+#-(.OV&S!%*15/"@FPFF829D1H%P1<=$\!-=I^ZRAM/S;M(K@Z;.&:#O0M7
M1R>-)NPXZM6 566B7AD8#-H=D*/[O$IC=HNI) "P'0?$%HW8V\DD!31!LUE4
M]D ;/)> D\L%R:B-6#/&GKH?/1ID/QXJ);'\&J<N&_*",[3#O;!S(B>_L]!P
MQ]KXD@/#Z"+&.6H9>!84FU(K?H'=0-RN4+'33($]AZ9! 4V:1W1&PPI ?U9@
M2?]8P=R)4U(/4G55EJFR55T60 +9K;.VKE K;)FS@+8)@@@/1)UV77"G!UDH
M,9GKLC886S2.:[MZ.0>!N!Q5%H@)MH7QTJJJQ9\/FSSF6-I\/)'(,?A>KQ_R
M5$)QK2NZK/VQVC:Q=IOL&&D[.*$<:#JW7)?N++*%'@H)OLB,-QQL&=9+$!3L
M. 1QKA]&)(B<==YRAH1?RA%<J;2NJ)=EF/B#9]+=DNX'?S/2_1E//^?0)CBK
MB44T-GJS==(^; "4J;*Z2+QV'W,BKBMD4K3-3B+5XJMK93%&$A K,D<J:W'V
M?:&C\F>WN.B5_)*@'J*.H(C89J_=^Z8+.(-9IL!?98#^G>41D6<T(G3YR$=+
MT&UG0IT"B)&MB*7;-#@E8,O [N9K2.Q2HO<UXBI7OR3\E67=;3(A-7FS@T3:
MR3VJ46N7R)'R%(5SC1>L$%&^LS22+3&VDI&J.ZPJH:HKVHK&P0C#[B#OFFG;
M-ED[Z2Y>13ZE.9[U-;=E,[R6\.<QT41BN43-%M?YE;!.C NQZPK%N8#&\V(P
M(HJO7/V:P"Z'[KQ&8*9]8[41IW$OBH4\'^YR1C-D$,R@\.<:W&2G<\5P('WK
M:Q21$&5FC'NE+@SGV47VR@TGCW2(EDG^^J-:@UQ,T\@0;)+O[I?";:A[GPCY
M9H$S=/^)HNVM57G-?^-#LLN>RP:--/.%Y7-YFH=2,_<C15(/PH1 2-G8%A=U
M2?>42U3Q+A@J4/5I'U/!ZS9^?*!^KI$K"F)4HA18@9TNS8638PI(28WOM5$V
M9N77_$HAITM@U:HB#@;P_<>EF>:EY,MNZ0NNU5N>LWV\["[?\L-2OGQ;G]*'
M1[>RL 9UJ>"1%[>1N+I;5*_Z>;' EX:W+2/LHW\A'O&?4Q'/3-DZ>3Y+E^#-
M4U2*4%*=@DOH!#?@V?-^J)XS(&$>-Y(&@O AK(X?"W.C$5:%BV&.Y>N2[BOC
M;H-G$*Q&FC2X:7@?-QA 0? 1@\16:]%[2]I]?F5F:N([CQM(V4)@X'PSI0F?
MK5G/T!N?R7ZZ+;&>%^)L6VG\(Q>FSI?"/#/+@K?4#3J>K3DJ-C'2W81FB12L
M''[<,*BT-DS2UD&)Y>MG5Z,F*YO&8M-9.EZ1QPV#8B!^L6-/JL$F<UX/%K=I
M-ORA%I_5R MNH>V$VR.WI18[VO;@],ULSM"E8%W\QR&"7P_\>,Y!?\Q0%L9?
MM9=862%&3Y@RLN"__@K^)YZ$#"GZ>"[M^KBA<.D7%G))BQBM"5<72>)6WND8
M_&D:/24M-*9VPFP&[BXAPF/UN!TV42/(!YDHNK?4BQ"RUSC@N*K+;L,[3%9)
M]_%=6 MNPIJY9G7[+^B.+U<+L_R-GC_R 0* J4MYS\%[,=!ET3BJ8HNX00<1
M2D X %++QK%0OABIU3_F]!$!*SJQK@#"IWJ&-(*:K4CEO8\H;TM[TMX=&ZCO
M81QJNL33Q@3V?!5>A9OJR)=&3 J\A8?O>02MX 09'[:CO!K&V=X,NHYEQ@;@
MUZK0!C0?IT4Y5(EIK4G%%PTRL\YN/U:@S-\X%YQVX6K1/*AG-);2;T823K."
M5BATYYH+*N5$ZB(X1F-+W]L"@^!&JI:3U7P!%:$([!#7R]A<IC^]QU?I498O
M:W3']WYB(]5@S%6H?FTPP->9SP#3>7"J72'F1=;2Q64O='R$4GGN2&B]U_5/
M^&@4T5D;=[<?8TY,XA'(K+A&@B3&3#F=%#4C%JTW%U<W/7%F!WFC3)Y6O+-]
M2F@W8SQB!OU@\Z)1"VB3B1U;LH.S=#/.&^O$;8.R($=):46*XGQ;GKCPPH^K
M-?L\5@D5@B-CGVF5@".@-?5]A)Y0BG(#FA 45[&$U@M$#VPUK%[9-DQFQNQE
MN6B%UM?L'G,E--[^'-NKG)FV"GNQE<^V1C+V)9NN<HG.7%+=0T//GLN%5FP:
MEK\<Z12I-L!Z$ 9S*-[(B*X&5L'Y13E;YZ[HS%R]VUE%]Q+9ZCW76,>ZV:!E
MG.JV;UOB% L$"CWTNH7RB_:"'BWS(?O$9#Z" G8DH%U80;4-FHP2GPKNB4F<
M(+HF;A9TR$A200V.@R*FIG(Z/CEP]7S;3MWM[1JV9-@TANX[>);I5<OT\E<J
MG8/C#%O>^%L(<X=QZ8B[SKAP5?$;M:@/5'FO9NQA:+3]??4M-ZCP9=L86:I8
M<2;#23A7A=@#]A#*YA GJ;RJC_?2MZ@2;B2FF:>'MEKN L(3ESJL2:*WIM96
M^="=_84P5L;0UUZ0/.W4J09R-#S1P-=XV+/QPI2>(-'9K"/#%O4/=UO1TR9W
M.84.DG9Q_+^W'F HF_R&+C4P_W>T<_%T?SVGO??F%#]=G?#BN3K!5B>\>*Y.
M>.#OE7R]OY2"-V=%'[+\/E6V/-XE4L@YMI4!$!_84G>C !W]73(SH%6@]]&X
MUL3Y#?YD/$2,TK"/8$E$4&2J.01 1D\CRB?3%F)U?8W)$VM2YDF5%C\I](Q"
MM[UV50!\N^B_A$]N>2=J]GH]]J+0I:E]$<[GM[E1OMYA&3_J=][Z?;;]%U[P
M N2LO9K0BYGU<CX[R4,9+ MJ^-<MY,2 >KN?-D@K'_9G2'/!NKGQ]\_J#\7I
M.QSZU0\;^QO'OT!4!.Y&4:733FT/G[B3X(%5-.__B-!.[_+RHG=U>BY^O'QW
MTKL4U[V;_M7YS6W]-Z[^:+.;\2M?X9\%:^VQ^=Q+>.QD^KK]F8=,HA>V VQF
MQ^RX"S#^W75W8#SE8AV3O9OY;+4]]K&P?K;+MS*30\2W,YOFF>ERI?=>_YE0
MHR'=O0@3([9 @3QVKCQ"PG)F@;],$<).B=7COY( UM,'(E3N-+NM3]=KJR@]
M7?, 4_1'S2[>G(O;TXMSP*E;>. &W(#@C^+]*::U4C!J_A'(3X#@+%A^!GJT
M0=/B_K^PLU94>N#JIV4&L$K@^G0,]_(YAK,QW,OG&&X1#; JIN/D>/9ORCWI
MWP?^7:8&]M5?MG]J_V3+6VDP8'N#Y[,OR_@I_Q[Q8W3[U;-N6]U^]??4[:^B
MQR=_3CUN[^1GY.\OZA(%\R>9U .4]Q^LZV^_2J]M!_#P[ZMN.QU<!)4+>VG^
M:?#@[;"@-8!4:JT%3]U6($;8_P\QHC'(KRTG.R?OSG[!_-O.3_VWE\?_#U!+
M P04    " ! <5!91*V$2']"  #L9P$ '    &5A,#(Q-S<X-3 Q97@T+3%?
M,3@P;&EF92YH=&WM?6MSV];5[G?.\#_@^#0=\@PM2[:3)K;K&4JB8[6RI%>2
MXV0ZG7=  I00@P +@)+97W_6;5\!D/1%3FRS,W5L$L2^K;WNZUG/7EZ^.G[>
M[3Q[.1H>PG\#_-^SRZ/+X]'S9P_XO_#M _GZV?[IX6_!Q>5OQZ._WYOF6?4D
MV-N=5\%E,HO+X"2^#<[S69@-^(-!<!$7R?0>_!!^>N;^;IRGT08_?AK,PN(J
MR9X$^.CNTZ"*WU7WPS2Y@H^*Y.JZNO?\V?[ST;OK9)Q4P>.=O6</]F'J9W<V
MZ.^+LDJFRWO/_YJ-R_G3SS+4R>CH\N7H/+A\>7017(P.7I\?7?X6G)SB)R/U
MP='H(C@ZN3P-WKP\.GCI/0M_'_TZ.C\XNACN'X^"E\-?1L'^:'02G(]^/KJX
M')V/#H,W,(C_PN')(?SPX.7PY.=1MW-P^NK5T<7%T>E)4!_;_O(%_! )97@Y
M@CG!(,='PY.#4?#Z#+X=GN!<7IU=XJ,OSD]?R23.A_3)ZY/#4>WEPX-+?.O>
M3X\>#;J=(7SP:@3/'08]?/"O:?2?1?[4??ZO!7W8'^ BX(^#@]/SPZ.3GX]_
M&P2OAKA]E[ %\-87M'I8T,7I,:UV='89G+T^OW@]/+D,8$-QPO#4P>41[)H]
MUVZ'E@A3N5PQ[7/_9<-?AD?'= [N/@SP6=BN80#O/[F '^,W.,^+U_O_@/'A
M]P,:PMFP\]'_O#XZIUE<=#NP2PV3P'/$-],FT%'0:0_/SHZ/#F@J?%C6SXZ'
M;RYV/#+"U_@D=P%+PQ?0V0J1C60>]F]QSV&_SXY'AS^/:#8'IR<G(UXDSR;8
M/ST9!B^.#D?P]/G/,N'7L''RO46M^^>G_QR=WS\<#8]AWV'C3NF*')_"!M.8
M^,QO<$*OX3*8^>Y\);QA$F=57-Q[_F9X?BZ4!50&%_4"3N?E\!Q.!DX [R3L
M[L7EZ<$_/\=L/M^Z]W[<#8Z/7L!B#XY&0,_(?\[/[O1T6Q9Y2=1_,#H^OC@;
M'@"#^?N]W7OT[[/AX:'ZM\SF-HFJ:Y2:N]\]#3:5H$]A^D44%_<G>9J&\S*&
MN<C?[I'0?G9YK@:XB8LJF82IFG25S^^)8']V>>A-XWN<10,!\]3NE\E_8YX?
M"-D7IT!EUI[>GX:S)%T^62?\WX1%$695<'$=%G'Y)/C7__[OO]4.XCM1SSC<
M?(8D\S_E_$[AC4D6IL%162[";!('AV$%KSV=5/DX+H*]OPV"A[L/']NSA3_.
M>>,?T.D_KQ/<Y^$DGV84^3#)HAA?NKOS?9+=>T[<NYV]$(>W^4O0JZZ34LGB
M9Z_5R3][\/JYDL5PAX \IPG,M[H.JP&<8Q'<A.DB#HIX$B<W<30@"AD$\$52
ME4%8EC#5$E\>6^]^"?<Y+NQ7@UH H\,"DBK%MRSF>1;@C^#.SN ]6124B_'O
M\:2".T%?I,DLJ<(JR>'U\&S\+BXF21G3H_C]),^BA+^^CHL8B&0*[PK*N,)I
M5]>#(*S@X650P7[C&V#*]$BW@S^/@(SHA_G4G_U1!N\%DANI(9'DG'W".? ;
MYT4"?\*4OW^RNQO,=V8[00_/^K>\>!L<)!4/W\>G/9+]J=OQQKV$K8!EX)KJ
M0XX759#E%2Z]B&D= QP6-JV<%,DXIK/"><T7Q>0ZA%E/BWP6$"-.IG%P,4EB
MN#Y >$?99 <V)SB,T_ 6;GVW,\F+>5[PP-Z<#O+9'#;1.4HX/!P:"2$HB6\$
ML(GPY Q^?U'ED[>#8!XJROG+[L[N[NY>,,?#P:<;AM _]$@&7HO/RB2"7EC:
M5!)&>$-F0%1TD NX(+@ISLM=_F:_'I0G>%+O%APD,!<8,,_BP/E5MT-O#NC^
MJ&]@)6D:P+;'_UD J0C-:HHYP[?!)I=!%$^3+(Z"!%8(\\8M?M@;]UM%X5WR
MC#^.6\G2>0)[.P&<S"%N#%]@/)8=L%_".=SX%,1&)&QA4<)?D:B1\G,D_5O<
M7;6G?._E+*[#FY@.81:'69)=E885X.8C0R/^%O))+ H8&Y9ZI@A@>%7$,1)3
M[5[6'W&O [*2*!@NKF '@I_H<C\*0J#I*X=Z%>-2)%? #&'GPBHOEL23BKC*
MOV6Z>$ATH>X0$<57L!O\)[[Z/>;0"_LR#;,AQ XMJ;UCV(WP2<W,2 TK06C/
M@>FA7AP%XZ7+P&;A$MG7+(R 3\&5N+W.TYC$>H;,N_+$9T'_14D,TQ!!2F,V
M"DM+0(YCN()\,7WYAG.*XA34BF*I.*BZ++"B,(@6Z1(%_V2!*YB&DQ)T@A1%
M_WQ)TS@[?$'_0*D VH*L,[X_"Y,TZ,$#\M>PJL+)-=[<OMJKD[P2AJ]GGK!&
M O.=P0(R&)A9#(J:,K#\6,, W5@>E^ 7TB'9)&S$S9L$#H"'B,,B36 #4?=(
M^B1R>GO]X+(((^!<L#G,+7H)?(G/9XO9F!^W'BEAZ3,06V4BC.:B@A^%101D
M6(&6Q;SL#$@RCTAT-HJBJ(\S8$[:A[6G:7ZK7D@Z$@QJ="_0U/ XRS")6-*R
MIB<L6 Z3O@BO@%E>X0L,_9)4)$4%GW!%<U#.XPGJGI$ZAW ^3\%6&J>-AP7G
M?)L@8<$[RBEN3A%,PO(:MO6O18E;#OMS'4_>!E$1WF9(C6'P&H@UCKH=V*D*
MAAR'V=M@D:5Q6;)*";^G?^@%SXM\$D<+&,>9GMF^"6AF,6Q9D+SO"D#@G>3P
MY-O[N;)Q&I:I]8P"% U8+VQ[EJO]QHLRBR/X*T[F:A'B?L8Q43Y)RZ!:SNE]
MYCOX"H1I6"3_I8N(]Z';P1<U[;$9=@>_OP4*+I'(D$#@-TC/5TH*RP4&M1R.
MI%@VD <*<>N5^(OY];)$>SC%*UP4,2I:* LM1N4QA@68$*G];F!XFO&!L@#C
MR WWZ"N\ 4Y 9Z&512V2U:/XKG$<&VL#: 66-EVDJ3#)9'*-9!(W+$\O(%@U
M_RG1*6CB:<J<\%:QA0)/[E'?O>*R%KR)P%K4#(A-M9%,4JJ+R'MLC;X3G %K
M1W:M%B@C6/.%O5JD%4X )8%L;,D,&:P$G+-6S"N@I-3B3AMLN:>LQ=,I:O/P
M6[A$P*J$\^2+2A-:Z^ME<CA MV-&@&F'&>I?0"JN>F[=QW4O18J_-">L"$6=
M(J\"9$M&^B18QWD1 0>X)N;)%N;Z(?1K%:,M%W"X>L]Y!NZ0BL62C"1+"&D(
M)53C%>YVA+R4B-E?@+A %H<R!AXDNWY>Z<$S>D7]MHM@C*]R^-> B!8I9:Y,
M,3UZK^P[U*A)D<C7MICW'JXUF5L5C(%<!-%B#+W;2HM14EB'F8HN85-P7;<?
MN$H[?ESB=&6, 0L:L$SP0WOL0:-4,^:JM;^X22# 'L,&=#L?M@.:=IJ_U7*C
M-B>T^UGEH@<MQ:#;(5'6)QX%5#C/\>);IC5(PYLD0JZ"QM0\7)+M+3M9%_AL
M!8,T8E%T#;=2!"-R4.8H-9';!_[5[2AW$^X2[=N*)>R@:N;=53HZ\DW%0"OP
MDG RB><5.1 ]A@>*[N1MEM^F<73%NTIGSAXPV)(ET'E8(NV*DHV;4+);2MX$
M^C+\)IQ?#SP%2BOD-O=LD4^>"Z/&/4!K\;FJG!,/84DUO@-7L$49D[Y<$U%T
M0M%.F$.6%9FO0FN@9"NW&.JXG\X ^R SZ,]@BNG1_\_]^\&+)$ZC)R!%K^*G
M,,1_%NA3@YD$]^\K)_GAT2]JFCSX_2J?PR,/YY6:SOUQ7E7Y[$GP WXFT0/U
MV7X*]!CL[7P/<RWS-(E@"GKA]8"'?B>-LMLP"#G@S4X^>P S;)CL&,C\[7TV
MUYX 2>,*[5?_T/!J7)0]/6NW6X>TMO$![B-OW;=,8;UQD[%/S)/M?&1NEDF"
M3'652_(O0#R[EK^UYIQ=XT/U';0-<])6[98_@ FH3^] I%FWXWBQVFTGSVBR
M7)9L58'5,45^[BDQ3 D2O2#/(6K]62[J-#!^$%I725FQ4[_;(29/I\R?&TT[
M47&U9JDD$V312KJ/R$!2_18E33TDMT(EAB#-I/+$E#V45KY6CP5_S^H^JS M
M2>W2%EJ[]XH4!]JU\9*\PF+%"&5/]&&I=PE5&TNO9N/AP!+#PNF*F@+O;%7V
M'0,$WEXEI#.-9=/0!9: 4D56P[]ZP_O[_:#W:__?^$5OV$<]%W;UR==WS7YX
MA/)D_13N/_P;"A/8B^#OY'_2-MR3;J<G_K%?W@S/E 9C.]&2V2R.$B#]= DT
M"X<5^:ZM]8ZF1"RC9DL;;"K0$4'#-7Y*5"&-00+Z&5(],5OC-@K[ZO:27RH*
MEZQ3J[OCK +(NO<0#(8-1@'+<\4P]DNU&4;F]CS&D DN3BX'L(E%&A;H7J.?
M7.<P@KH?GC/Q? $[]\/N+L@Q?,,Y_93YSLFK"V06LT5Z15JF$EO %&+X&]R,
MTH1BTO"V)*.']MN:[( ]H<('\[FM12MN$2=D9?3>M5)$M_.I2 (/9,GC[">1
MF#DF5JDEK9H ['4V2>:P6CV55V'Q%GA]2$YZ8/C,"O;3/$<^<A4<[YR!42B'
MH3\V 6CM&5)2P>R%=G]J:[=U58ZW>@VE:\J+%B0\-B&4&M4AU3K^*79/ -G>
MYD3D]',KR TGGTW2!;U 7'_.D\;&GZ0Y&UH?,K'^!C<(YY(T,)SW8B4U;T_S
M9H?=CK]M*Y[^&/ZS=@-A0UIVT+^F?ZR$^#,(J7T44G8B@*C,E G JK;$E(@1
M/L6S^N8W[5>U::Q#V6%.K1FB;+S-%VF$&ACID7C%*(E(J\.^(QO]P!/TRY)Z
M2QY+DW!4>UBNHW[;;8R9'Z[BB!JC>0)T:^W7:G!D?6+3Z(\]V/=0%H_J88""
MSTRB*;3/#1O&?B_4WE$9:'?*-1VLXFR/@+/U?M)!7BO/8SBI' >M=J>Q8E^%
M;V/%T)6)!%=U L^$$S278,63TC.2,%B$O$_;(J['7GS'E+65\PCX\3PO*>U%
M6WTD<H@:[;CBUY#[\(G=; ^?!J>D_)5/< *R6T^#7S#1#+[^7%ZXS7?C@_UU
M]C:H#7@:7"[GL,YA$8Z3R=/@))S%O$DG.2[]H>-;4[_";[YJO]\70=[&FZ8M
M!LN/UNV0E!E($N>25,2!LATF&&2J*'E&)?)@^+<H=>S%1!TF*8:F1&*2-HI9
MW:CO)0WV25*RER5-2#')0?BBBX+# 49!9F.%YS.&Z<];#1[EZB&K!/@TD&#)
M::7R118CTZTLTPN7VJ^9:F(?.1'OU5,/9.:M)E5O3#'7FDU">;(_/7FT&X3U
M2!SP9@K% 8=^_&3W87NXL@]&ZIAV^?3RX'_V<4+XEU_K)KV]FVQ'M&PD"4HR
M%GJY9"VOV#YO6,=5 G.;M%* 9!4W;"6=ILQ:C4!Y5S($&G-3IH92'[WS^I!3
MOS)S)/ 5RLBS)'L+S!R^D9-& @D#2O *,9GG*LPD1842MZ^ E5$H<!+'3"%P
M(IB!/EUDDTI%XW@4G"Y/JL^[/,O+BGQUH),8^FUUD /#U_,EEV<OZI/2@;DE
MI/-A_+*D=W<[TS ID"W@(CCCF73%YC>3X\2^RA03C>)Y3.P"CZP(09/ //84
MQ!L[6*[R'-/?4-&1VW]F<DAIM%GX>UX0N:(#%N5,;+B#I0716=C)%7B&'-\$
M.M%A4E2NW<R1@3AM8L[5C]_!C"4MA"^H]H_.PR0BQ=G.._FV=!G#[/%^?YE\
M/@H3H(>;/%W,T!C"A%)DKC=Q@;)[M01P&-<JMD\Y(;;3]H]@^TPGR/N[G<8T
MC#OB_2OWUJY]^,#-_21"H=O92"H$GT$HH.19(Q6"SR042 BND K!9Q(*)'W6
M2X7@SH4"II"NE0K!UR<4/BQB')F(\:L83BQ+)F4M<?PK#*WOO=\V)6:;5,)7
MDW/P-7H!W7B[[85A$I2,O7K0V21CFOP'3NRCS'*I*G!"TT#'W0X.<1B3+R<O
MEL#@L?A'C5E=%_GBZIIXD3R$_ HK # ;/<2*A.  ?I%'"5SV<@DL=J;#/;C>
M-\,#I_S/L&D:0,0@7#MVF&%TB5V>)![DA70G)2XV[)M$ 1BR.5$@,'D"<^1'
M5;59F@!JXZ0I8VE VI9+,':3PI&%[O<]-VS-I1;<)(V^0JHPJ51%&' 6E4K>
M[>B:DL9I#&S_GN0CRK;JR!GS:?6<>BH+_5";*H.-8I5JJ 3>"E]V7D\NL$IC
MG8"-ZY)66<Q15.!>F'(#X:OJ93S;IF1@>9"T!Q5OQ@^X'H6%0VM!B@X4K:C9
M:1Y8XK?R5B^T1:_UCZPUF=0;4JID/JA,IMLQ=3*!E,E\Q"*#GM;,5A:ANLFK
M3C)5MT.\S-^,I@VUSEO+V @3F%D_(Y8G5;VQR>6%M5#F_3B&/6%V>"V$/)4D
M=JH':;B\?L:WHF'K\M:K)P9!4LAOD-7D;OQSS3WM=CY7OK&N;C?%&':-%N>9
MW%V1EB(^8]TU4X"C(NP$1ZY( $TP+;5A*3G+)F_=$V$-)VQG!;947-7C)RXU
MN[GS3)CSL [^8$-#+ /!;O#2OR3;P\]I2"5$8N0:^3SP7"G*FB;_621<D1N%
M,[ 02EU C-8/R+4L3*LE<^HX!!K^R]Y@=W>W(77+S]W7C-B8E)8/CV]-4_K'
MQ@D"8)G\98\S-VTJPQ0(/$\Q</[RL/Z( E.X3I"O-;/M%5RH;W:C_MMU^?=6
M2995UXB_ZG9\#2"VJ)N-2J%'^'8"^E_I[;36$72ZNBT>PV!_L;Q_E+4D.6!I
MXXU*=-AAE:U>UZ&+>$*M"L&@3GF)>"BXSG!X166D2GS6%#!\^,7PXA+SGJZ*
M<(:&8XJUX&%)[-)L2A'CV&7-])+5(Y'L!$.I@E?YH$:JM',22ZA(^!HG5:KG
M2ZL\=$X_&*#IADH%JT1A"R\;*#KS]25@<+.0M&#'C>/+C+HGH,3A6!?5OJ V
M\=!00OE'FB=_O(&T2<CTT38Z*M'11]]F=/2+I&S4J9IM?QQ29U\T6/Y'7EZ/
M56[JJJ8F4[RFLFC= RN5Q2H*K>JR;H<2CTR]KY],)#!*$]*(O.S]=<9IL[H&
M'-DL/(A1*\XFNM)4X!Y<TQ2KJU5M&'Z\R(RKPQ/+6( MAH,'$Z'J+.W1>4L=
MSZ?P^!(K" .<&X&<J9PK\[IOG&&3I:KI^AQ5GK*D/.ES.D&+A'V]'D[3N+!<
M781(17Q5Z[7\=E6IK_T#*Y0]79:AQ[A-['IN(D4NC2"%SM7GOOGSO[%JA>!\
MXZR41'F\>Z+,PH&\@#-'T G81YQ!NE2'L('O$]X01HR,IBJSY9(RES!U.9[!
ME1@3YBX(KR4=TRVG%8KL=A0P23C.;V)7Z;=3/GV(F964*Z$IRZH11YCMA]/H
M%' 7$N)H1?[68Z<]AAC J@D5Y*%]""<J,J4]DWU5,N79L?Q6%/33I)A9GDQ=
M_3^H8:LA;@EJS991CPY?H*!RJH:F*!.Z8%V?8+-#MN:'##.V9-!Z9I\(Y=W/
M5;)WK#V)O="R1)AP75 LS29<;P#ZH><A1:0HF[9.-FSG<>$;AI@0Z(7FJ4H[
MW)U$US."4'A ;E;9@-GJ"6PC<]Q2O;^O/;;-2'9HO1FY&;_#0&.IJS_$)E75
M7)POC.@9\W2)0Z._R'4--24VV[MT&UHDV.J]22AY-!/VK>^2.1ZR3<M%+*A-
M6"]1Z20#S*76)U_&*,51N\>"<9QT(;YF!XP"U@@,3A!+0E,-PK<*;?2FZIQN
MQRO/01N68@P\G>:">+*!80MN@([AGZV;AR<G848W=3OD^/5UGN6XC3TL,#'0
M+=[3OOM4!%<<T=5M]YZ9:;50CI6TKO5/1,'$1&CXQ 44J9C-H[,P3<012:$%
M!_?2*(_Z-"S@@)W@!7IQWH7PCGB@0D8R98/D4DK(QI\O3)(\$$'CA8*G_[+'
MGC(4"3F!D"B158<#0<BM>#:OXLA)T->J._T"'U->W&Z'V!8/MBDETJ1V<5(#
M*2WCO!AB,T)5S05?A(J&@JC&HDB'=3"*0H>5LKO008<11R=[J]WK7&#\,!/8
M#XSJHU6@?,',/A _8ED7R.365'LJ:Y'M!E(0!%7+0K&&'2@+P;@=A5%)E4.:
MER55)=L 3KP*@EW5YH[ALEJQ(UD<VWH%7ILD]C2+Q 'EA)N0AK=2H(M[2TD)
MPJ$93B9?5!;F*P*41O$$<_YQTASJFI"_"O'92(> ;7A ;_R=TCTHE@F79]KF
M=W)<5E.C8LG=4U>]Y3H[Q2:U$F:;;=O:"IE^5'$B;LAO7 .V%."3O-MY4;#B
M OQ&F#H<Z,6D2.:J<#Z8FD=*_0ABWLX-OB%2<?TYS=F%YVK,8;]D2+MDR=TJ
M2K-ZGYVY4U.8F+U;<6BW/ESSK+H*U>1W8+E=F2B'EIO(@Z3^R$)L<!D$O9Y1
MP?3<F[&P^$GUC"@L)I!LT M4:2M<<GA#),"_)/W@<*7JOC&IZ9NG<\O0/X -
MNJ* YF7X3N)1(TF5,ODJ.L/"%?3UJ)2B:H3NU)QS0F-X:HH*!K(JR&E[9+^!
MTAR^TW8*<F)RVA N',TKJ,L>.P.D'A*"K1/H/;DC>J4Z*:PI%ZS;T2)+U[BV
MK5=N\>ID#+EE_&U!_T64<@T4!@QZ4ODI$T^!2%X_5]%F/)(!(M%>Y[?Q#<.8
M#P(&1%>QX1LR?U'!:ZAUX_0A,]U0IF/"TLT+&'C(A[=H0FDOHSCHZGHK6M6X
MAU8FR)"@KXA'O" T4\(_;8,SW4>DIX&+MJI]02T >+B?(O"XN-7@L>-S.(JJ
MY]-1>^"BBQG\?PJ2/!'_ 6@>LS'(RQ@5!D6O&M,3J C5($V=\N:F!"_BD&GJ
MNR@H8UU+9LJ?A7V_'Q$"0CZ)RU)P#UH@,*GT$%[+28YRO5KSOBA?->.#!K4,
M=*&DQ&V?I'%(1?,VTKJH,J2-2MF#SEOMM\R9!$.19Z@*K?8D?^,,>)/8V.-M
M;$QB8X^WL;$OAK)!M;!U"S#E* X$3& _S]^6]018<M"C/X0!'E"_+%%%D\RO
M,?Z*<S<9Q)1T1N3P618K!POHV2CR2AW*8E'16'B/B5O?D@7TWNG?L3D^W\K6
M<N?8=#]I2VG&(Q7X7/RP]3A8AM6AF.LQ&\M_2'7JEG?.?E]C",GQ>@_4P</R
MM:;$?G=Q[<C$E3%BE%]ZR)J(W<8AWP!6VTF-[%7Y54S2F%P""B[*\\4/02%)
MT4-4*J A[=LXBXL2C@#F,2$CDS2=*S"&T!"R7^VJH5:BZ(JQ3/)J;4 TK<B<
MS&)4ED#UR6_A-I;7R9RN>HN/0LS1 O0,P<K0_K7(GZ?QA"A0-Y4E:N(PP=XC
MK'+AS%:9FIV"-*RJ(AD+HNX9(S?880#$+Y.9J(4 XX"ED!OH':I?VK5EEGJJ
MEFK= @=SBF%JV=UISYH,"HU2K'U\/J!JR^;Y<ZPE5E/\J++/D#ZR-B&0/5">
M1'9QQ:MC !O"F30GX'(82ZJ'>*=T#CWW=H"9=3M\ZV''UT^'W]L"MH(WR)UA
M+&ELY,?+\LPD6+3P#_2OKMEH<X.\[88OFG9;I^':>8-@CX!V7%KQA84U.2R!
MA-GR0Y4[6W,;+7 RU\-JQ9=:O)?Z'0Z-C718 U1\R2\ELR*T?ATP-HB>?6$'
M <(TO\H7&BS1^I5!8A2'[OOM<[>S=J.QXPB6@@5AK;E.W.!;'[A THH.3-8!
M)KPVLSAMW$["=()H<F))M\"^,)N2(X(Y@HT-:N)P4FF[M5BD0BB%AJ<K'6BZ
MRG)7)Q5?(>3[&H;&W[U:[$[*)AVOI!\W4K"4:EUR82F@AZ&?EK5I?W/CXDST
M&@P.5,V03<#Z$H6^24H#.@!H%^S@!C8.2]+:[M)FX#1 \; E.7HH9-6-E)=D
M]3-6Y<E25^SP*O(7Q>(8<>N K"Q8"K@7L6P7S)IN%E")=3T;R-N5T+@'ZSFW
M]'93;JP6'N;-SZ)7N0QX#D&4E),B;@(K5 =';6M*Q:,:L^[]\*34IM7%N+.Q
M1"\?O+/!)]Q8K1=\T,Z2QXWRTB5RZ[0(7*,S#'ROE3HGTGRSW(XDPAMO4,%?
MBNB@K Q2-B>P%>%DJ=V>+@&3U])Y*6S#&/:B6CKN.A\Z2BX2N@N19S3<_XT6
M&#,_]K5M?5(4$"N5XFQDOI5R3IO2'K\.2P/[[]7OVJE&'*]S=D9'4EA?QK#_
M@GRQR"YB6"RQ74[P,9%7JQ+Z,S+\.R>4)F6U)@N33/](0L2@I#2=66O;16WF
ML7\V7:X\^C9-F(*94U-J3D4V34%4NX:>*PF2"6L5&8::N%Y>!(PF:JORG",A
M<GH'.CNGJ4,D?^/UAPQUWR;5XV# N2@PLR+6,UO \4UP4OD"*(G<T2XI4YW)
M@?\[+WA?_TEEI<2!^D0.9RRNH' DZ48;&1[6B>QP1A_^3(V.=G5!FUE+1FZ(
M(3H-7^Q:'D6J^*Y4@%@S&J1)3=DHO<5%#6!V /.@]DA^"YP-J,Z2=)H%M/@,
MZ-";-62<L*VU.X0[,$D'GD^CIAAO9GF4B<HAH53"T(8^H#B4V@ 0R.MWX-8"
M,6&/CY5CMUH4V"4_>B,?[_STTW<8E-!9Z"JPK/5)E1UDHT&[M=[V+OV$+]1\
M]WT(VTG#L4^UVW&/=0T>_6;&LIV=(YDR<HE] (L9Y2)2>5U,J!Z4=*)RYM<Y
M)1IZP;@<W:U@W>25F*N&0/X4853YAK3OGW3;@_9=]P$R5[LEKN.TR4_"%N'*
MW5'(##E:2@LZ&K040*\89O:AB$J];N.TFWL<6^@&IC;QASU@GI%;U:C2LE9U
M3+MT5B(7QV[Z8^X;+*6LBH5@,">8AC?C[IL4!1:/NLD6427*\*,$S@)9- 8$
MJV4;6JV]?>0V .VHH&-T9]03FT\IV>QY[_M-L]0F4> <)X]P!\K51&2!ACR2
M[YK-Y_9KB6T),CN9(>@IRW?.VUG,95/ 5H[1_X=E@W3MRJ10N6.PW:!-I-S"
MR'<5&[N3S\;J$XZ=K'U+U#\F(C$N'B7<H+*$T4T1O,M%CEP>!%]I'Q+-5<QM
M\@ISWSPO\55K2FLU>;CS80JGG:$<H;- ?'SE'Y"64K:4_@KQ8>ZB-=/WVR"O
M!'F__X:#O'\P=7]H1^Q'U!'[@+N6@X6A4__*;7=LB:"2RM/M'":4\1RQ37DQ
M3Y/F<CJWK37(PS2N^9\L_>D)13SFB.,1<M2<V_7$6>0$/$G089@0G7[&3$#!
M9OV;'#%M2EMAQ0PD0SK7?[/*(2SK1N6-)_6WJEHA!C(0P,F;/(F4EA?EBW$U
ML,+!*E:%LVA0NFONG]5Z89]#J=U.N1CSCI6;V("@<% L!),9BYJF.Y!PZ22?
MC;&+J5/E@[4STM(4[<)8CJM$4NAO9'[)X.4,RV&;1J<6(#=]W@_$LT)/08I]
M)JG85]R9;4X5-M%5Z<4DG">8TL:S]//WR;AV7)_LZ'+2<DTFJ)/!&SJIRR9E
M&=:#&D5N$(-\([UEYCV.&Y(&@CKYHECJ+5%55&TVA]3F<>HSV32.%Y@C EE.
M;C*,R3E]2S_2TC&#&@=?[97-!J51\VO=]5 Y9;5:QE)M/;C=F++S6N&)_!<K
M%)!%QGIRQ/:/2?/N=BC3U\VIL8P!['F@IT>X3L;\J6\*1VP)Z8E<%BKZ7XO+
M6#E"!IV,C [5]8R]G!8[='B?\8QO."OS/4VL!MTDG 3-L %J^L@#-!2H?Q&W
MVK%I*_FO\]'%Z/R7T>&_MYMB=VN\6(Q+TH(K58 ?G (-8J)NV5I+;>YE<RT]
MW48*:JC>C5K;L(7G%97!#90HR0G;-2TY\ZHM98 (G2=J%Y>4[/N_E=JZ@>,
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MEXL"X:W6^-*H4LU@$) M%\6S3+IU:;R0%=@H2:6;<GDM;JS9-#3F4L'?LI+
M.MV#/(NDPM[+7,"/)+KK8BE8&U3;'(HURJ9B6,<-CL)\$$R=<Z];XR7U'<=-
M3-YB_B %M[-( A:<M2TXW6:FM"]I$B\VFO+V.KL];<)J46!YQ0 S>#+Z&PJ
MA/\65Q.G*QZ5@.3D>LP3ZE2+'7*59[W221QD;.EKQS)MGA2:LK3(,<%_>(Y*
MBY!#2PJ!XU<-[>BZ@$EQA1N/(P$^KM%0T. \1BW$+396!INCL#;PQ=8 6S)Q
M6C ,54%3I-H\K^/J SL36)+';?99:\M0,<= [U@!:@'%B"@:K(<6US?'.>WJ
M,!=>*+ RD&IUT-PM&"6*IMHU'<3)DY+JR+?Z5F4N85JZ41Q(E5-Y$J)3U0%&
MW'V;+@IVK[A2,9&0;E/O M,*6PH7* T$&"WO526"HY1H?X'=C7+R,\',BBN5
M1$!.E@577N!0.KJO.RW[>Z'2M5QE*?;7C A=JQ=-9UU1JXTT5;4L&M)+@765
MZNJ:&0E*FD+F;'*AJE"_T(DE?2C+J325(,)G=/S#=K)Z[M0TO&7GK<J.']B5
MAW;,HS%I'G9DKJN@5"F'IEF9<8H.V&BEKA2:B'\C@=K>*3?QH6DW-CY0XXY7
M06.+&/$L!TW@72M?T^WX[R%D'S8$3','WSGO^ ]-%A-F-6#BHN$6@X *BS #
M4I).\(XLV?G)+OL,D9S+DJL(*:B+L2,&5"+R?(<,%52+C(,0?'G* #O-5_7H
MN<&>5,N7=#TQXWIL$5(7=TZ#=']!-:\FR$AX4HR0"OLUPYHH52)D,D%HA&\+
MY/\>>G[)W,TB8S%3R1?<[=N0D"@QETAJ2:1PS Y$-55AD9JQM#07J[E)2^XP
M4*H&#?<46/BIP;4E=T!U7>2+JVOA%S;(\\")+#.Z>&LAGU,R7&]6YD2 3;GY
MC:D)TA!WV-V7C9#X+;%5^@ W)A^C#%9]VT!X4W370C83\N;>>[58*X+:<9"-
M^55%9P^T?I6#$C -N:"Z+(';&9.F*(B#X1YSV%<BOMS>3Z?5VCJF>D:0M1O%
M!>NJNL:'Q7\EM8=:6L';5*FSYVIQ&=055@4B&!TPD8(P%>K>%'SO59S%19A:
M18WH0[W*B91J1A+Z-H#Z$ 8 .8LT[YV'A0O_VJ;O8.](CJ)RB$7E5A/;03ZZ
M*4BU9"'S' B40,]! .Q=@;U"2GO;3F6AK!!(GH8=_E=\&D\YC:\X:YTHFSAV
MM]/,LMLVI$6F>8*&4=VQ(IY*&HL)9\M;2D@\12H@E3$?<T-ULW01,Z%427.X
ME&OF"E7$5BILOJ7*DQ#M 2W[<1XM5;[L[W!GRXCS*Y2T&)A]';CJ3YQ)GTMK
M&Y&N^9JRVF?!W35H8I^/4W]NR; O[:.825A6*.M"A...@ &JKPYF7IL:296_
MUI:SN!FXMRF =JL3&X0.<!ZBK*"%L$PDGOZE2<.F,4F;'#3>PW4$B&E">439
M 2MH\2LFF$WBB'N[VT"B!!+W=K>1Q#\!W:[O!/0/ZQI;62EP7"7S$N ?H+)F
M2F,A5X+V4RM(!A!LF-DWB360%3K]"K#AJF8ONDDQ-V@@35GLI.!XV+-62^:A
MPA+_I@R;]7E&M=17QJI7NNOD;9;?IG%T%9=&T_+QQ%0KZ[5JDK11K*S,,(EV
M.-U(,$S*#8,Q#@"6=U +"4K.'?5/L5-)5>2'K!=0JG,I/Z+4-;#78P3ZIU9.
MR#A@J[8IFBO1,D_RC,S?@KT9HW=S[*0EKMH3+)U9%'S.41RFDH[($"YI2,J
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M9BTR,#(T,3 Q-E]P<F4N>&UL4$L! A0#%     @ 0'%062/&S.0\'   B*,
M !@              ( !S2$  &5A,#(Q-S<X-2TX:U\Q.#!L:69E+FAT;5!+
M 0(4 Q0    ( $!Q4%GZIP\>U3D  )85 0 =              "  3\^  !E
M83 R,3<W.#4P,65X,3 M,5\Q.#!L:69E+FAT;5!+ 0(4 Q0    ( $!Q4%F[
MV! ,X1D  -6"   =              "  4]X  !E83 R,3<W.#4P,65X,3 M
M,E\Q.#!L:69E+FAT;5!+ 0(4 Q0    ( $!Q4%E$K81(?T(  .QG 0 <
M          "  6N2  !E83 R,3<W.#4P,65X-"TQ7S$X,&QI9F4N:'1M4$L%
3!@     (  @ +@(  "35      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ea0217785-8k_180life_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ATNF="http://180lifesciences.com/20241016"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atnf-20241016.xsd" xlink:type="simple"/>
    <context id="AsOf2024-10-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2024-10-16</startDate>
            <endDate>2024-10-16</endDate>
        </period>
    </context>
    <context id="From2024-10-162024-10-16_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-16</startDate>
            <endDate>2024-10-16</endDate>
        </period>
    </context>
    <context id="From2024-10-162024-10-16_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-16</startDate>
            <endDate>2024-10-16</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-10-16" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-10-16" id="Fact000004">0001690080</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-10-16" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-10-16" id="Fact000010">2024-10-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-10-16" id="Fact000011">180 LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-10-16" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-10-16" id="Fact000013">001-38105</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-10-16" id="Fact000014">90-1890354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-10-16" id="Fact000015">3000 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-10-16" id="Fact000016">Bldg. 4</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2024-10-16" id="Fact000017">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-10-16" id="Fact000018">Palo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-10-16" id="Fact000019">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-10-16" id="Fact000020">94306</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-10-16" id="Fact000021">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-10-16" id="Fact000022">507-0669</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-10-16" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-10-16" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-10-16" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-10-16" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2024-10-162024-10-16_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000027">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-10-162024-10-16_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000028">ATNF</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-10-162024-10-16_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-10-162024-10-16_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000030">Warrants to purchase shares of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-10-162024-10-16_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000031">ATNFW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-10-162024-10-16_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-10-16" id="Fact000033">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
